Sudden Death in Patients with Myocardial Infarction ar Heart Failure, or Both

New England Journal of Medicine 352, 2581-2588

DOI: 10.1056/nejmoa043938

Citation Report

#	Article	IF	CITATIONS
1	The Holy Grail of shock resuscitation*. Critical Care Medicine, 2005, 33, 2691-2692.	0.9	1
2	Cariporide in cardiac resuscitation—Does it really make a difference?*. Critical Care Medicine, 2005, 33, 2707-2708.	0.9	13
3	Noninvasive ventilation for postextubation respiratory failure: Perhaps not to treat but at least to prevent!*. Critical Care Medicine, 2005, 33, 2685-2686.	0.9	4
4	Heme oxygenase-1: A pluripotent sentinel limiting the systemic inflammatory response to extremity ischemia and reperfusion*. Critical Care Medicine, 2005, 33, 2701-2703.	0.9	11
5	Neurocardiology: Antifibrillatory effects of heart-brain interactions after myocardial reperfusion*. Critical Care Medicine, 2005, 33, 2708-2709.	0.9	4
6	Making tracheal intubation safer in the critically ill patient*. Critical Care Medicine, 2005, 33, 2716-2717.	0.9	17
7	Lung water measurements: Are we there yet?*. Critical Care Medicine, 2005, 33, 2699-2700.	0.9	0
8	Fresh frozen plasma: Friend or faux pas in critical illness?*. Critical Care Medicine, 2005, 33, 2714-2716.	0.9	6
9	An old spice with new twists: Curcumin, p38 mitogen-activated protein kinase, and apoptosis*. Critical Care Medicine, 2005, 33, 2703-2705.	0.9	3
10	Vasopressin: A tool as rescue therapy? Take care of dosages and adverse effects!*. Critical Care Medicine, 2005, 33, 2713-2714.	0.9	3
11	Prophylactic fenoldopam for renal protection? No, thank you, not for me—Not yet at least*. Critical Care Medicine, 2005, 33, 2681-2683.	0.9	21
12	Galileo and the discovery of truth: Why does tracheostomy reduce sedation and analgesia requirements?*. Critical Care Medicine, 2005, 33, 2698-2699.	0.9	4
13	Consideration before administering cytotoxic chemotherapy to the critically ill*. Critical Care Medicine, 2005, 33, 2689-2691.	0.9	7
14	Prevention of ventilator-associated pneumonia: "Freeze, don't move!â€*. Critical Care Medicine, 2005, 33, 2686-2687.	0.9	4
15	Sepsis: The changing times*. Critical Care Medicine, 2005, 33, 2700-2701.	0.9	0
16	Low-dose adrenocorticotropic hormone test is not ready for routine adrenal function testing in the intensive care unit*. Critical Care Medicine, 2005, 33, 2688-2689.	0.9	15
17	What hemoglobin value should one use in transfusing a critically ill child?*. Critical Care Medicine, 2005, 33, 2710-2711.	0.9	3
18	Tracheostomy for ventilated patients—Not when, but in whom?*. Critical Care Medicine, 2005, 33, 2695-2696.	0.9	26

TATION REPO

#	Article	IF	CITATIONS
19	So hypotension is common: But what are the best treatment goals for kids with severe traumatic brain injury?*. Critical Care Medicine, 2005, 33, 2711-2712.	0.9	3
20	Glutamine: A double edge sword in the intensive care unit?*. Critical Care Medicine, 2005, 33, 2692-2694.	0.9	17
21	Combining arginine-vasopressin with catecholamines during cardiopulmonary resuscitation: Mirror, mirror, on the wall, is there a best mixture at all?*. Critical Care Medicine, 2005, 33, 2705-2706.	0.9	3
22	Apolipoprotein E: From Alzheimer's to sepsis*. Critical Care Medicine, 2005, 33, 2696-2697.	0.9	8
23	Hydrocortisone in septic shock: Too much, too little, too soon?*. Critical Care Medicine, 2005, 33, 2683-2684.	0.9	10
25	Methodology ofÂtherapeutic trials: lessons from theÂlate evidence ofÂtheÂcardiovascular toxicity ofÂsomeÂcoxibs. Joint Bone Spine, 2005, 72, 451-455.	1.6	7
26	Mycobacterial lipoarabinomannans modulate cytokine production in human T helper cells by interfering with raft/microdomain signalling. Cellular and Molecular Life Sciences, 2005, 62, 179-187.	5.4	43
27	Therapies to prevent heart failure post-myocardial infarction. Current Heart Failure Reports, 2005, 2, 174-182.	3.3	19
31	Sudden Death in Patients with Myocardial Infarction. New England Journal of Medicine, 2005, 353, 1294-1297.	27.0	5
32	Sudden Death after Myocardial Infarction — Who Needs Prophylaxis, and When?. New England Journal of Medicine, 2005, 352, 2638-2640.	27.0	26
33	Early intravenous then oral metoprolol in 45â€^852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet, The, 2005, 366, 1622-1632.	13.7	839
34	Eplerenone. Pharmacoeconomics, 2005, 23, 1057-1072.	3.3	12
35	Effect of Dominant-Negative Epidermal Growth Factor Receptors on Cardiomyocyte Hypertrophy. Journal of Receptor and Signal Transduction Research, 2006, 26, 659-677.	2.5	14
36	Characterization of the Peri-Infarct Zone by Contrast-Enhanced Cardiac Magnetic Resonance Imaging Is a Powerful Predictor of Post–Myocardial Infarction Mortality. Circulation, 2006, 114, 32-39.	1.6	732
37	Highlights and summary of the 2006 Canadian Hypertension Education Program recommendations. Canadian Journal of Cardiology, 2006, 22, 565-571.	1.7	8
38	Prediction versus prevention of sudden cardiac death. Lancet, The, 2006, 367, 1639-1641.	13.7	5
39	Modern physics for the modern physician. Lancet, The, 2006, 367, 1641-1642.	13.7	1
40	ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Journal of the American College of Cardiology, 2006, 48, e247-e346.	2.8	1,280

#	Article	IF	Citations
41	Remodelage ventriculaire gauche postinfarctus. Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique, 2006, 2006, 17-20.	0.0	0
42	Intensive Care After Resuscitation from Cardiac Arrest: A Focus on Heart and Brain Injury. Neurologic Clinics, 2006, 24, 41-59.	1.8	11
43	Cardiac Arrhythmias in Women. Revista Espanola De Cardiologia (English Ed), 2006, 59, 609-618.	0.6	17
47	Predictive Value of Microvolt T-Wave Alternans for Sudden Cardiac Death in Patients With Preserved Cardiac Function After Acute Myocardial Infarction. Journal of the American College of Cardiology, 2006, 48, 2268-2274.	2.8	181
48	The Year in Heart Failure 2005. Journal of Cardiac Failure, 2006, 12, 1-9.	1.7	142
49	Aldosterone antagonists: a new treatment option for patients with post-myocardial infarction heart failure. Cardiovascular Revascularization Medicine, 2006, 7, 234-236.	0.8	5
51	Arrhythmic death and ICD implantation after myocardial infarction. Heart International, 2006, 2, 12.	1.4	0
52	Arrhythmic Death and ICD Implantation after Myocardial Infarction. Heart International, 2006, 2, 182618680600200.	1.4	0
54	Implantable Cardioverter-Defibrillators. JAMA - Journal of the American Medical Association, 2006, 295, 809.	7.4	238
55	Sudden Death in Patients With Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both. Yearbook of Cardiology, 2006, 2006, 442-443.	0.0	0
56	Sudden Death in Patients With Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both. Yearbook of Medicine, 2006, 2006, 322-323.	0.1	0
57	Implantable cardiac arrhythmia devices-Part II: Implantable cardioverter defibrillators and implantable loop recorders. Clinical Cardiology, 2006, 29, 237-242.	1.8	13
58	Aldosterone blockade in post-acute myocardial infarction heart failure. Clinical Cardiology, 2006, 29, 434-438.	1.8	4
59	Cellular Alternans: A Mechanism Linking Calcium Cycling Proteins to Cardiac Arrhythmogenesis. Annals of the New York Academy of Sciences, 2006, 1080, 216-234.	3.8	26
60	Nephrotoxicity with cyclooxygenase 2 inhibitor use in children. Pediatric Nephrology, 2006, 21, 1893-1897.	1.7	23
62	Introduction. American Journal of Cardiology, 2006, 97, 1-3.	1.6	26
63	Role of Aldosterone Blockade for Treatment of Heart Failure and Post–Acute Myocardial Infarction. American Journal of Cardiology, 2006, 97, 34-40.	1.6	80
64	Determinants of Sudden Cardiac Death in Patients With Persistent Atrial Fibrillation in the RAte Control Versus Electrical Cardioversion (RACE) Study. American Journal of Cardiology, 2006, 98, 929-932.	1.6	18

		CITATION REPORT	ſ
#	ARTICLE	IF	CITATIONS
65	Anterior Wall Acute Myocardial Infarction. American Journal of Cardiology, 2006, 98, 1150-1155.	1.6	31
66	Sympathetic hyperinnervation and inflammatory cell NGF synthesis following myocardial infarction in rats. Brain Research, 2006, 1124, 142-154.	ן 1 2 . 2	122
67	Life and Death of Cardiac Stem Cells. Circulation, 2006, 113, 1451-1463.	1.6	360
68	Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejecti fraction â‰ 3 0%. European Journal of Heart Failure, 2006, 8, 295-301.	on 7.1	38
69	Angiotensin Receptor Blockers May Increase Risk of Myocardial Infarction. Circulation, 2006, 114, 838-854.	1.6	226
70	Review: Aldosterone Inhibition Reduces the Risk of Sudden Cardiac Death in Patients with Heart Failure. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2006, 7, 15-19.	1.7	13
71	Navigating the Crossroads of Coronary Artery Disease and Heart Failure. Circulation, 2006, 114, 1202-1213.	1.6	320
72	ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Circulation, 2006, 114, e385-484. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the	1.6	1,031
73	prevention of sudden cardiac death: A report of the American College of Cardiológy/American Hea Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythr	rt nias) Tj ETQq0 0 라7g	BT /Overlock 10
74	Rhythm Association and the Heart R. Europace, 2006, 8, 746-837. Antireflux Surgery Normalizes Cyclooxygenase-2 Expression in Squamous Epithelium of the Distal Esophagus. American Journal of Gastroenterology, 2006, 101, 1458-1466.	0.4	36
75	Prognostic value of ventricular arrhythmias and heart rate variability in patients with unstable angina. Heart, 2006, 92, 1055-1063.	2.9	48
76	Mechanisms of Sudden Cardiac Death in Myocardial Infarction Survivors. Circulation, 2007, 115, 2451-2457.	1.6	77
77	Novel Mechanisms of Valsartan on the Treatment of Acute Myocardial Infarction Through Inhibitic of the Antiadhesion Molecule Periostin. Hypertension, 2007, 49, 1409-1414. Addendum to acceptersonal and Public Safety Issues Related to Archythmias That May Affect	n 2.7	64
78	Consciousness: Implications for Regulation and Physician Recommendations: A Medical/ Scientific Statement From the American Heart Association and the North American Society of Pacing and Electrophysiology―Public Safety Issues in Patients With Implantable Defibrillators A Scientific Statement From the American Heart Association and the Heart Rhythm Society. Circulation, 2007	1.6	67
79	1170-1176. Causes of death and reâ€hospitalization in cardiogenic shock. Acute Cardiac Care, 2007, 9, 25-33	. 0.2	36
80	Improving end-of-life care for patients with chronic heart failure: "Let's hope it'll get better, when I know in my heart of hearts it won't". Heart, 2007, 93, 963-967.	2.9	153
81	Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure. Circulation, 2007, 116, 1482-1487.	1.6	528
82	Mental Stress Hemodynamic Responses and Myocardial Ischemia: Does Left Ventricular Dysfuncti Alter These Relationships?. Psychosomatic Medicine, 2007, 69, 495-500.	on2.0	8

#	Article	IF	CITATIONS
83	A 59-Year-Old Man Considering Implantation of a Cardiac Defibrillator. JAMA - Journal of the American Medical Association, 2007, 297, 1909.	7.4	7
84	Inequitable distribution of implantable cardioverter defibrillators in Ontario. International Journal of Technology Assessment in Health Care, 2007, 23, 354-361.	0.5	14
86	Effects of carvedilol early after myocardial infarction: Analysis of the first 30 days in Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN). American Heart Journal, 2007, 154, 637-644.	2.7	22
87	Management of Post-Myocardial Infarction Patients with Left Ventricular Systolic Dysfunction. American Journal of Medicine, 2007, 120, 109-120.	1.5	16
88	Sudden death prophylaxis in heart failure. International Journal of Cardiology, 2007, 119, 291-296.	1.7	6
89	American Society of Nephrology Presidential Address 2006. Journal of the American Society of Nephrology: JASN, 2007, 18, 1038-1045.	6.1	35
90	Novel mutation in the SCN5A gene associated with arrhythmic storm development during acute myocardial infarction. Heart Rhythm, 2007, 4, 1072-1080.	0.7	58
91	Addendum to $\hat{a} \in \infty$ Personal and Public Safety Issues Related to Arrhythmias that May Affect Consciousness: Implications for Regulation and Physician Recommendations: A Medical/Scientific Statement from the American Heart Association and the North American Society of Pacing and Flectrophysiology $\hat{a} \in A$ Heart Rhythm. 2007. 4. 386-393.	0.7	22
92	Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: The VALIANT experience. Heart Rhythm, 2007, 4, 308-313.	0.7	21
93	Right Ventricular Dysfunction Assessed by Cardiovascular Magnetic Resonance Imaging Predicts Poor Prognosis Late After Myocardial Infarction. Journal of the American College of Cardiology, 2007, 49, 855-862.	2.8	182
94	Noninvasive Risk Assessment Early After a Myocardial Infarction. Journal of the American College of Cardiology, 2007, 50, 2275-2284.	2.8	316
95	In Vivo Effects of Myocardial Creatine Depletion on Left Ventricular Function, Morphology, and Energy Metabolism—Consequences in Acute Myocardial Infarction. Journal of Cardiac Failure, 2007, 13, 230-237.	1.7	17
97	Effects of fish-oil supplementation on myocardial fatty acids in humans. American Journal of Clinical Nutrition, 2007, 85, 1222-1228.	4.7	185
98	Prevention of sudden cardiac death. , 0, , 449-462.		0
101	Future directions of myocardial fatty acid imaging. Journal of Nuclear Cardiology, 2007, 14, S153-S163.	2.1	11
102	An evaluation of post-resuscitation care as a possible explanation of a difference in survival after out-of-hospital cardiac arrest. Resuscitation, 2007, 74, 242-252.	3.0	17
103	Remodelling of action potential and intracellular calcium cycling dynamics during subacute myocardial infarction promotes ventricular arrhythmias in Langendorff-perfused rabbit hearts. Journal of Physiology, 2007, 580, 895-906.	2.9	43
104	Engraftment of connexin 43-expressing cells prevents post-infarct arrhythmia. Nature, 2007, 450, 819-824.	27.8	386

#	Article	IF	CITATIONS
105	Temporal Variations in Microvolt T-Wave Alternans Testing after Acute Myocardial Infarction. Annals of Noninvasive Electrocardiology, 2007, 12, 98-103.	1.1	11
106	Sudden Cardiac Death: Epidemiology, Mechanisms, and Therapy. Current Problems in Cardiology, 2007, 32, 501-546.	2.4	71
107	Mortality in Patients With Left Ventricular Ejection Fraction â‰ 9 0% After Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction. American Journal of Cardiology, 2007, 100, 793-797.	1.6	46
108	Genetic predisposition and cellular basis for ischemia-induced ST-segment changes and arrhythmias. Journal of Electrocardiology, 2007, 40, S26-S29.	0.9	21
109	Implantable cardioverter defibrillators for prevention of sudden cardiac Death. Clinical Cardiology, 2007, 30, 3-8.	1.8	6
110	Indications for implantable cardioverter defibrillator use for primary prevention of sudden cardiac death. Current Cardiology Reports, 2007, 9, 371-380.	2.9	1
112	Treatment of heart failure with ACE inhibitors and beta-blockers. Clinical Research in Cardiology, 2007, 96, 193-195.	3.3	18
113	Optimizing care of heart failure after acute MI with an aldosterone receptor antagonist. Current Heart Failure Reports, 2007, 4, 183-189.	3.3	11
114	Inhibiting the renin-angiotensin system with ACE inhibitors or ARBs after MI. Current Heart Failure Reports, 2007, 4, 190-197.	3.3	8
116	Mechanisms and potential therapeutic targets for ventricular arrhythmias associated with impaired cardiac calcium cycling. Journal of Molecular and Cellular Cardiology, 2008, 44, 31-43.	1.9	55
117	Timeâ€Dependence of Appropriate Implantable Defibrillator Therapy in Patients with Ischemic Cardiomyopathy. Journal of Cardiovascular Electrophysiology, 2008, 19, 784-789.	1.7	47
118	Time Dependence of Arrhythmias in ICD Patients. Journal of Cardiovascular Electrophysiology, 2008, 19, 790-793.	1.7	1
119	Risk Stratification Using Tâ€Wave Alternans: More Questions Waiting to be Answered. Journal of Cardiovascular Electrophysiology, 2008, 19, 1043-1044.	1.7	37
120	Sudden cardiac death: influence of diabetes. Diabetes, Obesity and Metabolism, 2008, 10, 523-532.	4.4	18
121	Comparison of Left Ventricular Ejection Fraction and Inducible Ventricular Tachycardia in ST-Elevation Myocardial Infarction Treated by Primary Angioplasty Versus Thrombolysis. American Journal of Cardiology, 2008, 101, 153-157.	1.6	15
122	Sudden Cardiac Death in Patients With Stable Coronary Artery Disease and Preserved Left Ventricular Systolic Function. American Journal of Cardiology, 2008, 101, 457-461.	1.6	23
123	Introduction to ACCORD-PMI: The Advisory Council on Care Optimization to Reduce Death Post-MI. American Journal of Cardiology, 2008, 102, 1G-4G.	1.6	0
124	Device Therapies in the Post-Myocardial Infarction Patient with Left Ventricular Dysfunction. American Journal of Cardiology, 2008, 102, 29G-37G.	1.6	5

IF

CITATIONS

Relation of Mortality to Failure to Prescribe Beta Blockers Acutely in Patients With Sustained Ventricular Tachycardia and Ventricular Fibrillation Following Acute Myocardial Infarction (from) Tj ETQq0 0 0 rgBT (Qverlock 10 Tf 50 74 125 Cardiology, 2008, 102, 1427-1432 Workup of the Cardiac Arrest Survivor. Progress in Cardiovascular Diseases, 2008, 51, 195-203. 3.1 Implantable Cardioverter–Defibrillators after Myocardial Infarction. New England Journal of 127 27.0 124 Medicine, 2008, 359, 2245-2253. American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying Patients at Risk for Sudden Cardiac Death. Journal of the American College of Cardiology, 2008, 52, 1179-1199. 128 241 A Critical Appraisal of Implantable Cardioverter-Defibrillator Therapy for the Prevention of Sudden 129 2.8 318 Cardiac Death. Journal of the American College of Cardiology, 2008, 52, 1111-1121. Benefits of the Implantable Cardioverter-Defibrillator. Journal of the American College of Cardiology, 2008, 52, 1122-1127. 2.8 Prognostic impact of left bundle-branch block in the early stable phase after acute myocardial 131 1.7 5 infarction. International Journal of Cardiology, 2008, 130, 438-443. Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality. American Heart Journal, 2008, 155, 2.7 87-93. High-risk myocardial infarction in the young: The VALsartan In Acute myocardial iNfarcTion (VALIANT) 133 2.7 29 trial. Amerićan Heart Journal, 2008, 155, 706-711. The use of periinfarct contrast-enhanced cardiac magnetic resonance imaging for the prediction of 134 2.7 late postmyocardial infarction ventricular dysfunction. American Heart Journal, 2008, 156, 498-505. Comprehensive Adrenergic Blockade Post Myocardial Infarction Left Ventricular Dysfunction. 135 2.2 2 Cardiology Clinics, 2008, 26, 79-89. Risk Factor Assessment: Defining Populations and Individuals at Risk. Cardiology Clinics, 2008, 26, 2.2 355-366. A Comprehensive Approach to Management of Ventricular Arrhythmias. Cardiology Clinics, 2008, 26, 137 2.2 4 481-496. American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying Patients at Risk for Sudden Cardiac Death. Heart Rhythm, 2008, 5, e1-e21. 61 Aldosterone Receptor Blockade in Patients with Left Ventricular Systolic Dysfunction Following 139 2.2 7 Acute Myocardial Infarction. Cardiology Clinics, 2008, 26, 91-105. American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying Patients at Risk for 140 903 Sudden Cardiac Death. Circulation, 2008, 118, 1497-1518. Prediction of Sudden Cardiac Death in Patients With Coronary Heart Disease. Circulation: 141 2.6 7 Cardiovascular Imaging, 2008, 1, 175-177. Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic 142 2.2 heart failure. European Heart Journal, 2008, 30, 338-345.

ARTICLE

#

#	Article	IF	CITATIONS
143	Implantable cardioverter defibrillator following acute myocardial infarction: the '48-hour' and '40-day' rule. Europace, 2008, 10, 536-539.	1.7	3
144	Association of <i>NOS1AP</i> Genetic Variants With QT Interval Duration in Families From the Diabetes Heart Study. Diabetes, 2008, 57, 1108-1114.	0.6	59
145	Sudden cardiac death and left ventricular ejection fraction during long-term follow-up after acute myocardial infarction in the primary percutaneous coronary intervention era: results from the HIJAMI-II registry. Heart, 2008, 95, 216-220.	2.9	89
147	Does It Matter Why and How Patients With Heart Failure Die?. Circulation: Heart Failure, 2008, 1, 89-90.	3.9	3
148	Sudden Death After Myocardial Infarction. JAMA - Journal of the American Medical Association, 2008, 300, 2022.	7.4	208
149	Home Automated Defibrillators after Myocardial Infarction. New England Journal of Medicine, 2008, 359, 533-535.	27.0	2
150	Prediction of fatal or near-fatal cardiac arrhythmia events in patients with depressed left ventricular function after an acute myocardial infarction. European Heart Journal, 2008, 30, 689-698.	2.2	225
151	Predictors of Severity and Survival in Acute Pancreatitis. Pancreas, 2008, 37, e54-e61.	1.1	35
152	Non-Invasive Tests for Risk Stratification in Ischemic and Non-Ischemic Cardiomyopathy. , 0, , 213-239.		0
154	Electrotonic remodeling following myocardial infarction in dogs susceptible and resistant to sudden cardiac death. Journal of Applied Physiology, 2008, 104, 386-393.	2.5	11
155	Clues at the Scene of the Crime: Sudden Death in Dialysis Patients. Peritoneal Dialysis International, 2009, 29, 23-25.	2.3	0
158	Tratamento de uma coorte de pacientes com infarto agudo do miocárdio com supradesnivelamento do segmento ST. Arquivos Brasileiros De Cardiologia, 2009, 92, 464-471.	0.8	9
159	Home ECG monitoring of high-risk post-myocardial infarction patients. Orvosi Hetilap, 2009, 3, 263-267.	0.2	1
160	Indications for ICD and cardiac resynchronization therapy for prevention of sudden cardiac death. Expert Review of Cardiovascular Therapy, 2009, 7, 181-195.	1.5	4
161	Sudden death and associated factors in a historical cohort of chronic haemodialysis patients. Nephrology Dialysis Transplantation, 2009, 24, 2529-2536.	0.7	144
162	MRI of the Microarchitecture of Myocardial Infarction. Circulation: Cardiovascular Imaging, 2009, 2, 169-170.	2.6	3
163	The Confirmatory Trial in Comparative-Effectiveness Research. New England Journal of Medicine, 2009, 361, 1498-1499.	27.0	4
164	Defibrillator Implantation Early after Myocardial Infarction. New England Journal of Medicine, 2009, 361, 1427-1436.	27.0	605

#	Article	lF	CITATIONS
165	The Challenge of Predicting and Preventing Sudden Cardiac Death Immediately After Myocardial Infarction. Circulation, 2009, 120, 185-187.	1.6	8
166	Stem Cells Are Not Proarrhythmic: Letting the Genie out of the Bottle. Circulation, 2009, 119, 1824-1831.	1.6	39
167	Outcomes of Early Risk Stratification and Targeted Implantable Cardioverter-Defibrillator Implantation After ST-Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention. Circulation, 2009, 120, 194-200.	1.6	68
168	Total absence of ST-segment resolution after failed thrombolysis is correlated with unfavorable short- and long-term outcomes despite successful rescue angioplasty. Journal of Electrocardiology, 2009, 42, 73-78.	0.9	6
169	Macrophage depletion suppresses sympathetic hyperinnervation following myocardial infarction. Basic Research in Cardiology, 2009, 104, 681-693.	5.9	88
170	ICD implantation in patients with ischemic left ventricular dysfunction. Current Treatment Options in Cardiovascular Medicine, 2009, 11, 3-9.	0.9	0
171	Sudden adult death. Forensic Science, Medicine, and Pathology, 2009, 5, 210-232.	1.4	28
172	Update on primary prevention implantable cardioverter-defibrillator therapy. Current Cardiology Reports, 2009, 11, 335-342.	2.9	2
173	Who should receive an implantable cardioverter-defibrillator after myocardial infarction?. Current Heart Failure Reports, 2009, 6, 236-244.	3.3	2
174	Primary prevention with ICDs, are we on the right track?. Netherlands Heart Journal, 2009, 17, 92-94.	0.8	7
175	Primary prevention with the ICD in clinical practice: not as straightforward as the guidelines suggest?. Netherlands Heart Journal, 2009, 17, 107-110.	0.8	9
176	Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trialâ€. European Journal of Heart Failure, 2009, 11, 1099-1105.	7.1	73
177	Indications for Implantable Cardioverter-Defibrillators Based on Evidence and Judgment. Journal of the American College of Cardiology, 2009, 54, 747-763.	2.8	88
178	Implantable Cardioverter-Defibrillator Therapy After Acute Myocardial Infarction. Journal of the American College of Cardiology, 2009, 54, 2001-2005.	2.8	16
180	Noninvasive risk stratification after myocardial infarction: Rationale, current evidence and the need for definitive trials. Canadian Journal of Cardiology, 2009, 25, 21A-27A.	1.7	19
181	Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Infarction Trial (VALIANT). European Journal of Heart Failure, 2009, 11, 292-298.	7.1	102
182	Ventricular Tachycardia and Sudden Cardiac Death. Mayo Clinic Proceedings, 2009, 84, 289-297.	3.0	118
183	Evidence-based analysis of risk factors for sudden cardiac death. Heart Rhythm, 2009, 6, S2-S7.	0.7	17

#	Article	IF	CITATIONS
184	Implantable Cardioverter-Defibrillator Therapy forÂPrimary Prevention of Sudden Cardiac Death: An Argument forÂRestraint. Cardiac Electrophysiology Clinics, 2009, 1, 105-116.	1.7	3
185	Heart failure enhances susceptibility to arrhythmogenic cardiac alternans. Heart Rhythm, 2009, 6, 251-259.	0.7	116
186	End-Stage Renal Disease and Sudden Cardiac Death. Cardiac Electrophysiology Clinics, 2009, 1, 61-77.	1.7	4
187	Risk stratification for sudden death in patients with coronary artery disease. Heart Rhythm, 2009, 6, 836-847.	0.7	48
188	Implantable Cardioverter Defibrillator Therapy for Primary Prevention of Sudden Cardiac Death—An Argument for Guideline Adherence. Cardiac Electrophysiology Clinics, 2009, 1, 95-103.	1.7	0
189	The Wearable Cardioverter Defibrillator—Bridge to the Implantable Defibrillator. Cardiac Electrophysiology Clinics, 2009, 1, 129-146.	1.7	0
190	Presumed arrhythmic death in consecutive survivors of acute myocardial infarction – implications for primary implantable cardioverter defibrillator implantation. Coronary Artery Disease, 2009, 20, 155-162.	0.7	2
191	Increased Apelin following Bone Marrow Mononuclear Cell Transplantation Contributes to the Improvement of Cardiac Function in Patients with Severe Heart Failure. Cell Transplantation, 2009, 18, 1311-1318.	2.5	24
192	Ventricular arrhythmia in coronary artery disease: limits of a risk stratification strategy based on the ejection fraction alone and impact of infarct localization. Europace, 2009, 11, 1639-1646.	1.7	45
193	Risk stratification of ventricular arrhythmias in patients with systolic heart failure. Current Opinion in Cardiology, 2010, 25, 268-275.	1.8	15
194	Management of sudden cardiac death risk in the very early postmyocardial infarction period. Current Opinion in Cardiology, 2010, , 1.	1.8	0
199	Role of the Automatic Implantable Cardioverter Defibrillator in the Post-myocardial Infarction Patient. Current Cardiovascular Risk Reports, 2010, 4, 321-326.	2.0	0
201	Cardiomyocytes hypertrophic status after myocardial infarction determines distinct types of arrhythmia: Role of the ryanodine receptor. Progress in Biophysics and Molecular Biology, 2010, 103, 71-80.	2.9	12
202	Predictors of Death and Occurrence of Appropriate Implantable Defibrillator Therapies in Patients With Ischemic Cardiomyopathy. American Journal of Cardiology, 2010, 106, 1566-1573.	1.6	36
203	Advancing geriatrics education: An efficient faculty development program for academic hospitalists increases geriatric teaching. Journal of Hospital Medicine, 2010, 5, 541-546.	1.4	16
204	Pharmacotherapy and hospital admissions before out-of-hospital cardiac arrest: A nationwide study. Resuscitation, 2010, 81, 1657-1663.	3.0	15
205	Bridging a Temporary High Risk of Sudden Arrhythmic Death. Experience with the Wearable Cardioverter Defibrillator (WCD). PACE - Pacing and Clinical Electrophysiology, 2010, 33, 353-367.	1.2	120
206	Optimal Timing of Implantable Cardioverterâ€Defibrillator Implantation After Myocardial Infarction: A Decision Analysis. Journal of Cardiovascular Electrophysiology, 2010, 21, 791-798.	1.7	7

#	Article	IF	CITATIONS
207	Is patient involvement during hospitalization for acute myocardial infarction associated with postâ€discharge treatment outcome? An exploratory study. Health Expectations, 2010, 13, 298-311.	2.6	24
208	The Riddle of Nonsustained Ventricular Tachycardia and Sudden Cardiac Death. Circulation, 2010, 122, 449-451.	1.6	2
209	Early Repolarization Associated With Ventricular Arrhythmias in Patients With Chronic Coronary Artery Disease. Circulation: Arrhythmia and Electrophysiology, 2010, 3, 489-495.	4.8	114
210	Relationship Between Nonsustained Ventricular Tachycardia After Non–ST-Elevation Acute Coronary Syndrome and Sudden Cardiac Death. Circulation, 2010, 122, 455-462.	1.6	109
211	Pathogenesis of Sudden Unexpected Death in a Clinical Trial of Patients With Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both. Circulation, 2010, 122, 597-602.	1.6	195
212	Long-Term Recording of Cardiac Arrhythmias With an Implantable Cardiac Monitor in Patients With Reduced Ejection Fraction After Acute Myocardial Infarction. Circulation, 2010, 122, 1258-1264.	1.6	235
213	The Apelin-APJ Pathway Exists in Cardiomyogenic Cells Derived from Mesenchymal Stem Cells In Vitro and in Vivo. Cell Transplantation, 2010, 19, 949-958.	2.5	31
214	The Contradiction of Appropriate Shocks in Primary Prevention ICDs. Circulation, 2010, 122, 2638-2641.	1.6	34
215	Effectiveness of prophylactic implantation of cardioverter-defibrillators without cardiac resynchronization therapy in patients with ischaemic or non-ischaemic heart disease: a systematic review and meta-analysis. Europace, 2010, 12, 1564-1570.	1.7	142
216	Relation between time from myocardial infarction to enrolment and patient outcomes in the Multicenter UnSustained Tachycardia Trial. Europace, 2010, 12, 1112-1118.	1.7	7
217	Timing of implantation of cardioverter-defibrillator after acute myocardial infarction. Europace, 2010, 12, 1057-1058.	1.7	0
218	Predictors of sudden cardiac death change with time after myocardial infarction: results from the VALIANT trial. European Heart Journal, 2010, 31, 211-221.	2.2	44
219	Early therapy following myocardial infarction: arguments for and against implantable cardioverter-defibrillators. Future Cardiology, 2010, 6, 315-323.	1.2	2
220	Is there new hope for sudden cardiac death prevention early after myocardial infarction?. Heart Rhythm, 2010, 7, 1598-1599.	0.7	3
221	Sudden cardiac death after myocardial infarction in patients with type 2 diabetes. Heart Rhythm, 2010, 7, 1396-1403.	0.7	83
222	The Wearable Cardioverter-Defibrillator. Journal of the American College of Cardiology, 2010, 56, 204-205.	2.8	5
223	Aggregate National Experience With the Wearable Cardioverter-Defibrillator. Journal of the American College of Cardiology, 2010, 56, 194-203.	2.8	268
224	Remodeled left ventricular myocardium remote to infarction sites is the arrhythmogenic substrate for sudden cardiac death. Medical Hypotheses, 2010, 75, 368-371.	1.5	3

#	Article	IF	CITATIONS
225	Increased αB-crystallin in hypothalamic paraventricular nucleus of rats with myocardial infarction. Neuroscience Letters, 2010, 484, 123-127.	2.1	0
226	Sudden cardiac death after PCI and CABG in the bare-metal stent era: Incidence, prevalence, and predictors. International Journal of Cardiology, 2010, 144, 263-266.	1.7	12
227	Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: The VALsartan In Acute myocardial iNfarcTion Trial (VALIANT). American Heart Journal, 2010, 160, 145-151.	2.7	33
228	The coin toss: Implications for risk stratification for sudden cardiac death. American Heart Journal, 2010, 160, 3-7.	2.7	11
229	Sudden cardiac death: epidemiology and risk factors. Nature Reviews Cardiology, 2010, 7, 216-225.	13.7	306
230	Mortality benefits from implantable cardioverter-defibrillator therapy are not restricted to patients with remote myocardial infarction: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Heart Rhythm, 2011, 8, 393-400.	0.7	37
231	Mortality benefits from implantable cardioverter-defibrillator therapy are not restricted to patients with remote myocardial infarction. Heart Rhythm, 2011, 8, 401-402.	0.7	0
232	Indications for a Wearable Cardioverter-Defibrillator. Cardiac Electrophysiology Clinics, 2011, 3, 339-347.	1.7	1
233	Death during acute myocardial infarction: Dodging the first bullet. Heart Rhythm, 2011, 8, 1467-1468.	0.7	1
234	Effect of reperfusion time on inducible ventricular tachycardia early and spontaneous ventricular arrhythmias late after ST elevation myocardial infarction treated with primary percutaneous coronary intervention. Heart Rhythm, 2011, 8, 493-499.	0.7	25
235	Sudden Cardiac Death Risk Stratification and Assessment: Primary Prevention Based on Ejection Fraction Criteria. Heart Failure Clinics, 2011, 7, 175-183.	2.1	3
236	Risk stratification early post-MI after percutaneous coronary intervention: Should programmed ventricular stimulation be revisited?. Heart Rhythm, 2011, 8, 500-502.	0.7	0
237	Why Are Implantable Cardioverter Defibrillator Outcomes in Practice Different from Clinical Trials?. Cardiac Electrophysiology Clinics, 2011, 3, 511-520.	1.7	0
238	Evaluation of the Young Patient Resuscitated from Ventricular Fibrillation. Cardiac Electrophysiology Clinics, 2011, 3, 593-608.	1.7	0
239	Microvolt T-wave alternans and beat-to-beat variability of repolarization during early postischemic remodeling in a pig heart. Heart Rhythm, 2011, 8, 1050-1057.	0.7	14
240	Microvolt T-Wave Alternans. Journal of the American College of Cardiology, 2011, 58, 1309-1324.	2.8	371
241	NGF and heart: Is there a role in heart disease?. Pharmacological Research, 2011, 63, 266-277.	7.1	50
242	Epidemiology of Sudden Cardiac Death in Patients with Heart Failure. Heart Failure Clinics, 2011, 7,	2.1	10 _

#	Article	IF	CITATIONS
243	Implanted bone marrow-derived mesenchymal stem cells fail to metabolically stabilize or recover electromechanical function in infarcted hearts. Tissue and Cell, 2011, 43, 238-245.	2.2	15
244	Implantable cardioverter defibrillators and cardiac resynchronisation therapy. Lancet, The, 2011, 378, 722-730.	13.7	45
245	Implantable cardioverter/defi brillator interventions in primary prevention: do current implantation criteria really predict ICD interventions?. Acta Cardiologica, 2011, 66, 145-151.	0.9	2
247	Utilisation of emergency medical service among Singapore patients presenting with ST-segment elevation myocardial infarction: prevalence and impact on ischaemic time. Internal Medicine Journal, 2011, 41, 809-814.	0.8	4
248	Sudden Cardiac Death: Epidemiology, Circadian Variation, and Triggers. Current Problems in Cardiology, 2011, 36, 56-80.	2.4	15
249	Sex-Based Differences in Cardiac Arrhythmias, ICD Utilisation and Cardiac Resynchronisation Therapy. Netherlands Heart Journal, 2011, 19, 35-40.	0.8	26
250	Prediction of sudden cardiac death: next steps in pursuit of effective methodology. Journal of Interventional Cardiac Electrophysiology, 2011, 31, 101-107.	1.3	20
251	Interdisciplinary strategies for arrhythmia program development: measuring quality, performance, and outcomes. Journal of Interventional Cardiac Electrophysiology, 2011, 31, 91-99.	1.3	1
252	Ventricular tachycardia and sudden death after primary PCI-reperfusion therapy. Herzschrittmachertherapie Und Elektrophysiologie, 2011, 22, 243-248.	0.8	4
253	Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia, 2011, 54, 2978-2986.	6.3	211
254	Diagnostic performance of computed tomography angiography for differentiating ischemic vs nonischemic cardiomyopathy. Journal of Nuclear Cardiology, 2011, 18, 407-420.	2.1	23
255	Indications for Implantable Cardioverter-Defibrillator Placement in Ischemic Cardiomyopathy and after Myocardial Infarction. Current Heart Failure Reports, 2011, 8, 252-259.	3.3	4
256	Cardiopulmonary resuscitation training of family members before hospital discharge using video selfâ€instruction: A feasibility trial. Journal of Hospital Medicine, 2011, 6, 428-432.	1.4	24
257	Timing of defibrillator implant after acute myocardial infarction: what's new?. Europace, 2011, 13, 455-457.	1.7	0
258	Predicting and Preventing Sudden Cardiac Death. Circulation, 2011, 124, 651-656.	1.6	55
259	Mineralocorticoid receptor antagonism: therapeutic potential in acute heart failure syndromes. European Heart Journal, 2011, 32, 2626-2633.	2.2	37
260	Circumstances and Outcomes of Sudden Unexpected Death in Patients With High-Risk Myocardial Infarction. Circulation, 2011, 123, 2674-2680.	1.6	18
261	Reversibility of Adverse, Calcineurin-Dependent Cardiac Remodeling. Circulation Research, 2011, 109, 407-417.	4.5	51

#	Article	IF	CITATIONS
262	Risk Stratification in Heart Failure Using 123I-MIBC. Journal of Nuclear Medicine Technology, 2011, 39, 295-301.	0.8	9
263	Sudden Cardiac Death Risk Prediction. Archives of Internal Medicine, 2011, 171, 1710.	3.8	1
264	Response to Letters Regarding Article, "OMEGA, A Randomized, Placebo-Controlled Trial to Test the Effect of Highly Purified Omega-3 Fatty Acids on Top of Modern Guideline-Adjusted Therapy After Myocardial Infarction― Circulation, 2011, 124, .	1.6	0
265	Risk Stratification for Arrhythmic Sudden Cardiac Death. Circulation, 2011, 123, 2423-2430.	1.6	155
266	Clinical practice of defibrillator implantation after myocardial infarction: impact of implant time: results from the PreSCD II Registry. Europace, 2011, 13, 499-508.	1.7	21
267	The Extent of Left Ventricular Scar Quantified by Late Gadolinium Enhancement MRI Is Associated With Spontaneous Ventricular Arrhythmias in Patients With Coronary Artery Disease and Implantable Cardioverter-Defibrillators. Circulation: Arrhythmia and Electrophysiology, 2011, 4, 324-330.	4.8	117
268	Long-Term Cardiovascular Risk of Nonsteroidal Anti-Inflammatory Drug Use According to Time Passed After First-Time Myocardial Infarction. Circulation, 2012, 126, 1955-1963.	1.6	102
269	Left Ventricular Ejection Fraction Assessment Among Patients With Acute Myocardial Infarction and Its Association With Hospital Quality of Care and Evidence-Based Therapy Use. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 662-671.	2.2	34
270	Sudden Cardiac Death Caused by Coronary Heart Disease. Circulation, 2012, 125, 1043-1052.	1.6	389
271	Primary prevention of defibrillator implantation after myocardial infarction: clinical practice and compliance to guidelines. Europace, 2012, 14, 490-495.	1.7	7
272	Risk stratification after myocardial infarction: it is time for intervention. Europace, 2012, 14, 1684-1686.	1.7	3
273	Sudden cardiac death and implantable cardioverter defibrillators: two modern epidemics?. Europace, 2012, 14, 787-794.	1.7	22
274	Refining the Indications of Implantable Cardioverter Defibrillator in Patients with Left Ventricular Dysfunction. Reviews on Recent Clinical Trials, 2012, 7, 197-203.	0.8	2
275	Non-invasive risk stratification for sudden cardiac death by heart rate turbulence and microvolt T-wave alternans in patients after myocardial infarction. Europace, 2012, 14, 1786-1792.	1.7	24
276	Troponin I as a prognostic marker of cardiac events in asymptomatic hemodialysis patients using a sensitive troponin I assay. International Urology and Nephrology, 2012, 44, 1841-1845.	1.4	16
277	Post-Infarction Sustained Monomorphic Ventricular Tachycardia. , 2012, , 512-561.		1
278	Ventricular arrhythmias and sudden cardiac death. Lancet, The, 2012, 380, 1520-1529.	13.7	217
280	Mild-to-moderate kidney dysfunction and the risk of sudden cardiac death in the setting of acute myocardial infarction. Heart Rhythm, 2012, 9, 540-545.	0.7	15

#	Article	IF	CITATIONS
281	Epidemiology and Genetics of Sudden Cardiac Death. Circulation, 2012, 125, 620-637.	1.6	522
282	Incidence and predictors of sudden death in patients having myocardial infarction — A population-based investigation in Taiwanese. International Journal of Cardiology, 2012, 157, 439-440.	1.7	1
283	Prevention of sudden cardiac death in patients with chronic kidney disease. BMC Nephrology, 2012, 13, 162.	1.8	27
284	Cardiovascular magnetic resonance characterization of peri-infarct zone remodeling following myocardial infarction. Journal of Cardiovascular Magnetic Resonance, 2012, 14, 24.	3.3	36
285	Antiarrhythmic Potential of Mesenchymal Stem Cell Is Modulated by Hypoxic Environment. Journal of the American College of Cardiology, 2012, 60, 1698-1706.	2.8	50
286	The pharmacokinetics and pharmacodynamics of valsartan in the post-myocardial infarction population. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 1469-1482.	3.3	2
287	Gender Differences in the Pathophysiology, Clinical Presentation, and Outcomes of Ischemic Heart Failure. Current Heart Failure Reports, 2012, 9, 267-276.	3.3	81
288	The Effects of Supplementation with Omega-3 Polyunsaturated Fatty Acids on Cardiac Rhythm: Anti-Arrhythmic, Pro-Arrhythmic, Both or Neither? It Depends…. Frontiers in Physiology, 2012, 3, 57.	2.8	14
289	The Relevance of the Primary Prevention Criteria for Implantable Cardioverter Defibrillator Implantation in Korean Symptomatic Severe Heart Failure Patients. Korean Circulation Journal, 2012, 42, 173.	1.9	10
290	The Timing of Implantable Cardioverter-Defibrillator Implantation in Patients with Heart Failure. Current Cardiology Reports, 2012, 14, 299-307.	2.9	1
291	Prediction of sudden cardiac death in patients after acute myocardial infarction using T-wave alternans: a prospective study. Journal of Electrocardiology, 2012, 45, 60-65.	0.9	26
292	Heart rate deceleration runs for postinfarction risk prediction. Journal of Electrocardiology, 2012, 45, 70-76.	0.9	49
293	Treating Cardiac Arrhythmias Detected With an Implantable Cardiac Monitor in Patients After an Acute Myocardial Infarction. Current Treatment Options in Cardiovascular Medicine, 2012, 14, 39-49.	0.9	6
294	A low pulse pressure predicts mortality in subjects with heart failure after an acute myocardial infarction: a post-hoc analysis of the CAPRICORN study. Clinical Research in Cardiology, 2012, 101, 29-35.	3.3	35
295	Early Echocardiographic Deformation Analysis for the Prediction of Sudden Cardiac Death and Life-Threatening Arrhythmias After Myocardial Infarction. JACC: Cardiovascular Imaging, 2013, 6, 851-860.	5.3	90
296	Wearable Cardioverter-Defibrillator Use in Patients Perceived to Be at High Risk Early Post-Myocardial Infarction. Journal of the American College of Cardiology, 2013, 62, 2000-2007.	2.8	170
297	Controversy surrounding the best time for ICD implantation after myocardial infarction. Heart Rhythm, 2013, 10, 836-837.	0.7	1
298	Sympathetic denervation of peri-infarct myocardium requires the p75 neurotrophin receptor. Experimental Neurology, 2013, 249, 111-119.	4.1	31

#	Article	IF	CITATIONS
299	Prediction of ventricular arrhythmias using cardiovascular magnetic resonance. European Heart Journal Cardiovascular Imaging, 2013, 14, 518-525.	1.2	38
300	Ambulatory ECG-Based T-Wave Alternans Monitoring for Risk Assessment and Guiding Medical Therapy: Mechanisms and Clinical Applications. Progress in Cardiovascular Diseases, 2013, 56, 172-185.	3.1	53
301	Clinical applications of T-wave alternans assessed during exercise stress testing and ambulatory ECG monitoring. Journal of Electrocardiology, 2013, 46, 585-590.	0.9	7
302	Inâ€Hospital Heart Rate Turbulence and Microvolt Tâ€Wave Alternans Abnormalities for Prediction of Early Lifeâ€Threatening Ventricular Arrhythmia after Acute Myocardial Infarction. Annals of Noninvasive Electrocardiology, 2013, 18, 530-537.	1.1	20
303	Dual neurohormonal intervention in CV disease: angiotensin receptor and Neprilysin inhibition. Expert Opinion on Investigational Drugs, 2013, 22, 915-925.	4.1	23
304	Insufficient compliance with current implantable cardioverter defibrillator (ICD) therapy guidelines in post myocardial infarction patients is associated with increased mortality. International Journal of Cardiology, 2013, 166, 421-424.	1.7	6
305	More than hormones: Sex differences in cardiovascular parameters after sleep loss in rats. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 44, 34-38.	4.8	9
306	Early mineralocorticoid receptor blockade in primary percutaneous coronary intervention for ST-elevation myocardial infarction is associated with a reduction of life-threatening ventricular arrhythmia. International Journal of Cardiology, 2013, 167, 73-79.	1.7	28
307	Psychological Distress and Arrhythmia: Risk Prediction and Potential Modifiers. Progress in Cardiovascular Diseases, 2013, 55, 582-589.	3.1	58
308	Syncope and Driving, Flying and Vocational Concerns. Progress in Cardiovascular Diseases, 2013, 55, 454-463.	3.1	11
309	Cardiac aetiology of cardiac arrest: Percutaneous coronary interventions during and after cardiopulmonary resuscitation. Bailliere's Best Practice and Research in Clinical Anaesthesiology, 2013, 27, 347-358.	4.0	1
310	Survival benefit of primary prevention implantable cardioverter-defibrillator therapy after myocardial infarction: Does time to implant matter? A meta-analysis using patient-level data from 4 clinical trials. Heart Rhythm, 2013, 10, 828-835.	0.7	13
311	A new animal model to study sudden cardiac death. Journal of the Chinese Medical Association, 2013, 76, 479-480.	1.4	0
312	Failure to reassess ejection fraction after acute myocardial infarction in potential implantable cardioverter/defibrillator candidates: Insights from the Translational Research Investigating Underlying disparities in acute Myocardial infarction Patients' Health Status (TRIUMPH) registry.	2.7	15
313	Anticoagulation in heart failure: current status and future direction. Heart Failure Reviews, 2013, 18, 797-813.	3.9	28
314	Causes and prevention of sudden cardiac death in the elderly. Nature Reviews Cardiology, 2013, 10, 135-142.	13.7	39
315	Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillator. European Heart Journal, 2013, 34, 2230-2242.	2.2	104
316	Prior myocardial infarction in the young: predisposes to a high relative risk but low absolute risk of a sudden cardiac death. Europace, 2013, 15, 48-54.	1.7	8

#	Article	IF	CITATIONS
317	Wearable Cardioverter-Defibrillators. Circulation, 2013, 127, 854-860.	1.6	45
318	Early Risk of Mortality After Coronary Artery Revascularization in Patients With Left Ventricular Dysfunction and Potential Role of the Wearable Cardioverter Defibrillator. Circulation: Arrhythmia and Electrophysiology, 2013, 6, 117-128.	4.8	111
319	Dilated Cardiomyopathy. Circulation: Arrhythmia and Electrophysiology, 2013, 6, 228-237.	4.8	93
320	Plasminogen activator inhibitor-1 5C/5G genotype is associated with early spontaneous recanalization of the infarct-related artery in patients presenting with acute ST-elevation myocardial infarction. Coronary Artery Disease, 2013, 24, 196-200.	0.7	3
321	Time-perspective in cardiovascular risk of NSAID use after first-time myocardial infarction. Current Opinion in Cardiology, 2013, 28, 683-688.	1.8	4
322	Evolution of Ventricular Tachycardia and Its Electrophysiological Substrate Early After Myocardial Infarction. Circulation: Arrhythmia and Electrophysiology, 2013, 6, 1010-1017.	4.8	18
323	Current Evidence Base for Use of the Implantable Cardioverter–Defibrillator. Circulation, 2013, 128, 172-183.	1.6	29
324	Primary Radiofrequency Ablation of Ventricular Tachycardia Early After Myocardial Infarction. Circulation: Arrhythmia and Electrophysiology, 2013, 6, 1215-1221.	4.8	5
325	Implantable Devices for the Management of Heart Failure. , 2013, , 270-280.		0
326	Diagnosis and Treatment of Asymptomatic Left Ventricular Systolic Dysfunction after Myocardial Infarction. ISRN Cardiology, 2013, 2013, 1-7.	1.6	4
327	Value of Early Cardiovascular Magnetic Resonance for the Prediction of Adverse Arrhythmic Cardiac Events After a First Noncomplicated ST-Segment–Elevation Myocardial Infarction. Circulation: Cardiovascular Imaging, 2013, 6, 755-761.	2.6	45
328	Hibernating myocardium results in partial sympathetic denervation and nerve sprouting. American Journal of Physiology - Heart and Circulatory Physiology, 2013, 304, H318-H327.	3.2	24
329	Life Vest. Circulation: Arrhythmia and Electrophysiology, 2013, 6, 5-6.	4.8	6
330	CMR imaging for the evaluation of myocardial stunning after acute myocardial infarction: a meta-analysis of prospective trials. European Heart Journal Cardiovascular Imaging, 2013, 14, 1080-1091.	1.2	23
331	Baicalein Preconditioning Protects Cardiomyocytes from Ischemia-Reperfusion Injury via Mitochondrial Oxidant Signaling. The American Journal of Chinese Medicine, 2013, 41, 315-331.	3.8	35
332	Inhibition of p38 MAPK During Ischemia, But Not Reperfusion, Effectively Attenuates Fatal Arrhythmia in Ischemia/Reperfusion Heart. Journal of Cardiovascular Pharmacology, 2013, 61, 133-141.	1.9	57
333	Arrhythmias in Women. , 2013, , 1039-1053.		0
334	Implantable Cardioverter-Defibrillators in Sudden Cardiac Death Prevention: What Guidelines Don't Tell. , 0, , .		0

#	Article	IF	CITATIONS
335	Effect of Hypoxic Paracrine Media on Calcium-Regulatory Proteins in Infarcted Rat Myocardium. Korean Circulation Journal, 2014, 44, 16.	1.9	2
336	The clinical challenge of preventing sudden cardiac death immediately after acute ST-elevation myocardial infarction. Expert Review of Cardiovascular Therapy, 2014, 12, 1427-1437.	1.5	5
337	Cardiac magnetic resonance infarct heterogeneity: is it ready to be used on patients for the prevention of sudden cardiac death?. European Heart Journal Cardiovascular Imaging, 2014, 15, 108-109.	1.2	2
338	Long-Term Arrhythmia-Free Survival in Patients With Severe Left Ventricular Dysfunction and No Inducible Ventricular Tachycardia After Myocardial Infarction. Circulation, 2014, 129, 848-854.	1.6	58
339	Present Guidelines for Device Implantation. Circulation, 2014, 129, 383-394.	1.6	28
340	QT Restitution Properties during Exercise in Male Patients with Coronary Artery Disease. , 2014, 19, 358-365.		0
341	The Impact of <scp>NSAID</scp> Treatment on Cardiovascular Risk – Insight from Danish Observational Data. Basic and Clinical Pharmacology and Toxicology, 2014, 115, 179-184.	2.5	26
342	A Novel Method to Capture the Onset of Dynamic Electrocardiographic Ischemic Changes and its Implications to Arrhythmia Susceptibility. Journal of the American Heart Association, 2014, 3, e001055.	3.7	16
343	Myocardial Viability and Microvascular Obstruction. Cardiology in Review, 2014, 22, 246-252.	1.4	4
344	Response to Letters Regarding Article, "Long-Term Arrhythmia-Free Survival in Patients With Severe Left Ventricular Dysfunction and No Inducible Ventricular Tachycardia After Myocardial Infarction― Circulation, 2014, 130, e179.	1.6	0
345	HRS/ACC/AHA Expert Consensus Statement on the Use of Implantable Cardioverter-Defibrillator Therapy in Patients Who Are Not Included or Not Well Represented in Clinical Trials. Circulation, 2014, 130, 94-125.	1.6	102
346	Right Ventricular Dysfunction Predisposes to Inducible Ventricular Tachycardia at Electrophysiology Studies in Patients With Acute ST-Segment–Elevation Myocardial Infarction and Reduced Left Ventricular Ejection Fraction. Circulation: Arrhythmia and Electrophysiology, 2014, 7, 898-905.	4.8	2
347	Angiotensin Receptor Antagonists to Prevent Sudden Death in Heart Failure: Does the Dose Matter?. ISRN Cardiology, 2014, 2014, 1-7.	1.6	7
348	Le futur de la rythmologie interventionnelle. Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique, 2014, 2014, 17-31.	0.0	0
349	Influence of heart failure symptoms and ejection fraction on short- and long-term outcomes for older patients with non–ST-segment elevation myocardial infarction. American Heart Journal, 2014, 167, 267-273.e1.	2.7	13
350	HRS/ACC/AHA Expert Consensus Statement on the Use of Implantable Cardioverter-Defibrillator Therapy in Patients Who Are Not Included or Not Well Represented in Clinical Trials. Heart Rhythm, 2014, 11, 1270-1303.	0.7	16
351	Effects of endothelin A receptor blockade in patients with ST-elevation acute coronary syndrome — A rhythmologic substudy. Life Sciences, 2014, 118, 430-434.	4.3	4
352	HRS/ACC/AHA Expert Consensus Statement on the Use of Implantable Cardioverter-Defibrillator Therapy in Patients Who Are Not Included or Not Well Represented in Clinical Trials. Journal of the American College of Cardiology, 2014, 64, 1143-1177.	2.8	118

#	Article	IF	CITATIONS
354	Impact of Cardiovascular Events on Change in Quality of Life and Utilities in Patients After Myocardial Infarction. JACC: Heart Failure, 2014, 2, 159-165.	4.1	91
355	Risk Stratification for Sudden Cardiac Death. Circulation, 2014, 129, 516-526.	1.6	131
357	Incidence of sudden cardiac death after ventricular fibrillation complicating acute myocardial infarction: a 5-year cause-of-death analysis of the FAST-MI 2005 registry. European Heart Journal, 2014, 35, 116-122.	2.2	90
358	Sudden Cardiac Death in Heart Failure. Cardiology Clinics, 2014, 32, 135-144.	2.2	25
359	Risk of Sudden Cardiac Death in Chronic Kidney Disease. Journal of Cardiovascular Electrophysiology, 2014, 25, 222-231.	1.7	27
360	A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure, 2014, 16, 1175-1182.	7.1	64
361	What is the optimal left ventricular ejection fraction cut-off for risk stratification for primary prevention of sudden cardiac death early after myocardial infarction?. Europace, 2014, 16, 1315-1321.	1.7	7
362	Evolution of Left Ventricular Ejection Fraction After Acute Myocardial Infarction. Circulation, 2014, 130, 743-748.	1.6	57
363	Survival of the Fittest. Circulation, 2014, 130, 737-739.	1.6	2
364	Principles of Primary and Secondary Prevention of Cardiovascular Disease. , 2014, , 1-44.		0
364 365	Principles of Primary and Secondary Prevention of Cardiovascular Disease. , 2014, , 1-44. Prognostic implications of left ventricular regional function heterogeneity assessed with two-dimensional speckle tracking in patients with ST-segment elevation myocardial infarction and depressed left ventricular ejection fraction. Heart and Vessels, 2014, 29, 619-628.	1.2	0
364 365 366	Principles of Primary and Secondary Prevention of Cardiovascular Disease. , 2014, , 1-44. Prognostic implications of left ventricular regional function heterogeneity assessed with two-dimensional speckle tracking in patients with ST-segment elevation myocardial infarction and depressed left ventricular ejection fraction. Heart and Vessels, 2014, 29, 619-628. Experimental model of transthoracic, vascular-targeted, photodynamically induced myocardial infarction. American Journal of Physiology - Heart and Circulatory Physiology, 2014, 306, H270-H278.	1.2	0 6 11
364 365 366 367	Principles of Primary and Secondary Prevention of Cardiovascular Disease., 2014, , 1-44. Prognostic implications of left ventricular regional function heterogeneity assessed with two-dimensional speckle tracking in patients with ST-segment elevation myocardial infarction and depressed left ventricular ejection fraction. Heart and Vessels, 2014, 29, 619-628. Experimental model of transthoracic, vascular-targeted, photodynamically induced myocardial infarction. American Journal of Physiology - Heart and Circulatory Physiology, 2014, 306, H270-H278. Wearable cardioverter defibrillator: A life vest till the life boat (ICD) arrives. Indian Heart Journal, 2014, 66, 68-72.	1.2 3.2 0.5	0 6 11 15
364 365 366 367	Principles of Primary and Secondary Prevention of Cardiovascular Disease. , 2014, , 1-44. Prognostic implications of left ventricular regional function heterogeneity assessed with two-dimensional speckle tracking in patients with ST-segment elevation myocardial infarction and depressed left ventricular ejection fraction. Heart and Vessels, 2014, 29, 619-628. Experimental model of transthoracic, vascular-targeted, photodynamically induced myocardial infarction. American Journal of Physiology - Heart and Circulatory Physiology, 2014, 306, H270-H278. Wearable cardioverter defibrillator: A life vest till the life boat (ICD) arrives. Indian Heart Journal, 2014, 66, 68-72. Effect of Left Ventricular Dysfunction and Viral Load on Risk ofÂSudden Cardiac Death in Patients With Human ImmunodeficiencyÂVirus. American Journal of Cardiology, 2014, 113, 1260-1265.	1.2 3.2 0.5 1.6	0 6 11 15 22
364 365 366 367 368	Principles of Primary and Secondary Prevention of Cardiovascular Disease. , 2014, , 1-44. Prognostic implications of left ventricular regional function heterogeneity assessed with two-dimensional speckle tracking in patients with ST-segment elevation myocardial infarction and depressed left ventricular ejection fraction. Heart and Vessels, 2014, 29, 619-628. Experimental model of transthoracic, vascular-targeted, photodynamically induced myocardial infarction. American Journal of Physiology - Heart and Circulatory Physiology, 2014, 306, H270-H278. Wearable cardioverter defibrillator: A life vest till the life boat (ICD) arrives. Indian Heart Journal, 2014, 66, 68-72. Effect of Left Ventricular Dysfunction and Viral Load on Risk ofÂSudden Cardiac Death in Patients With Human ImmunodeficiencyÁVirus. American Journal of Cardiology, 2014, 113, 1260-1265. Left ventricular ejection fraction overcrossing 35% after one year of cardiac resynchronization therapy predicts long term survival and freedom from sudden cardiac death: Single center observational experience. International Journal of Cardiology, 2014, 172, 64-71.	1.2 3.2 0.5 1.6 1.7	0 6 11 15 22 18
364 365 366 367 368 369	Principles of Primary and Secondary Prevention of Cardiovascular Disease. , 2014, , 1-44. Prognostic implications of left ventricular regional function heterogeneity assessed with two-dimensional speckle tracking in patients with ST-segment elevation myocardial infarction and depressed left ventricular ejection fraction. Heart and Vessels, 2014, 29, 619-628. Experimental model of transthoracic, vascular-targeted, photodynamically induced myocardial infarction. American Journal of Physiology - Heart and Circulatory Physiology, 2014, 306, H270-H278. Wearable cardioverter defibrillator: A life vest till the life boat (ICD) arrives. Indian Heart Journal, 2014, 66, 68-72. Effect of Left Ventricular Dysfunction and Viral Load on Risk ofÂSudden Cardiac Death in Patients With Human ImmunodeficiencyÂVirus. American Journal of Cardiology, 2014, 113, 1260-1265. Left ventricular ejection fraction overcrossing 35% after one year of cardiac resynchronization therapy predicts long term survival and freedom from sudden cardiac death: Single center observational experience. International Journal of Cardiology, 2014, 172, 64-71. The Role of the Wearable Cardioverter Defibrillator in Clinical Practice. Cardiology Clinics, 2014, 32, 253-270.	1.2 3.2 0.5 1.6 1.7 2.2	0 6 11 15 22 18 36
 364 365 366 367 368 369 370 371 	Principles of Primary and Secondary Prevention of Cardiovascular Disease. , 2014, , 1-44. Prognostic implications of left ventricular regional function heterogeneity assessed with two-dimensional speckle tracking in patients with ST-segment elevation myocardial infarction and depressed left ventricular ejection fraction. Heart and Vessels, 2014, 29, 619-628. Experimental model of transthoracic, vascular-targeted, photodynamically induced myocardial infarction. American Journal of Physiology - Heart and Circulatory Physiology, 2014, 306, H270-H278. Wearable cardioverter defibrillator: A life vest till the life boat (ICD) arrives. Indian Heart Journal, 2014, 66, 68-72. Effect of Left Ventricular Dysfunction and Viral Load on Risk ofÂSudden Cardiac Death in Patients With Human ImmunodeficiencyAVirus. American Journal of Cardiology, 2014, 113, 1260-1265. Left ventricular ejection fraction overcrossing 35% after one year of cardiac resynchronization therapy predicts long term survival and freedom from sudden cardiac death: Single center observational experience. International Journal of Cardiology, 2014, 172, 64-71. The Role of the Wearable Cardioverter Defibrillator in Clinical Practice. Cardiology Clinics, 2014, 32, 253-270. Incidence and predictors of sudden cardiac death in patients with reduced left ventricular ejection fraction in an era of revascularisation. Heart, 2014, 100, 1242-1249.	1.2 3.2 0.5 1.6 1.7 2.2 2.9	0 6 11 15 22 18 36 34

#	Article	IF	CITATIONS
373	Prognosis of Myocardial Infarction With Left Ventricular Dysfunction in the Coronary Revascularization Era. Circulation Journal, 2014, 78, 2483-2491.	1.6	12
374	Do Japanese Patients With Myocardial Infarction and Left Ventricular Dysfunction Require Prophylactic Implantable Cardioverter-Defibrillator Implantation?. Circulation Journal, 2014, 78, 2384-2385.	1.6	0
375	Usefulness of a wearable cardioverter defibrillator combined with catheter ablation for ventricular tachyarrhythmia storms after a myocardial infarction: A case report. Journal of Arrhythmia, 2015, 31, 257-260.	1.2	0
376	Temporal Trends in Clinical Characteristics, Management and Prognosis of Patients With Symptomatic Heart Failure in Japan – Report From the CHART Studies –. Circulation Journal, 2015, 79, 2396-2407.	1.6	89
377	Current Status of Primary Prevention of Sudden Cardiac Death With Implantable Cardioverter Defibrillator in Patients With Chronic Heart Failure. Circulation Journal, 2015, 79, 381-390.	1.6	52
378	Prophylactic Implantation of Implantable Cardioverter-Defibrillator for Japanese Patients With Heart Failure. Circulation Journal, 2015, 79, 297-299.	1.6	1
379	Prophylactic lidocaine for myocardial infarction. The Cochrane Library, 2021, 2021, CD008553.	2.8	23
380	The Effect of Elapsed Time from Myocardial Infarction on Mortality and Major Adverse Cardiac and Cerebrovascular Events in ICD Patients. PACE - Pacing and Clinical Electrophysiology, 2015, 38, 1448-1455.	1.2	1
381	Long-term Cost-effectiveness of Endoscopic vs Open Vein Harvest for Coronary Artery Bypass Grafting. Journal of Cardiovascular Diseases & Diagnosis, 2015, 03, .	0.0	0
383	The impact of hospital-based cardiac rehabilitation on signal average ECG parameters of the heart after myocardial infarction. Research in Cardiovascular Medicine, 2015, 4, 4.	0.1	2
384	Sudden Cardiac Death in Coronary Artery Disease. Cardiovascular Medicine, 2015, , 621-656.	0.0	0
386	Performance of CMR Methods for Differentiating Acute From Chronic MI. JACC: Cardiovascular Imaging, 2015, 8, 669-679.	5.3	25
387	Value of cardiac MRI to evaluate ischemia-related ventricular arrhythmia substrates. Expert Review of Cardiovascular Therapy, 2015, 13, 565-576.	1.5	0
388	The Spectrum of Epidemiology Underlying Sudden Cardiac Death. Circulation Research, 2015, 116, 1887-1906.	4.5	474
389	Utility of the Wearable Cardioverter-Defibrillator in Patients WithÂNewly Diagnosed Cardiomyopathy. Journal of the American College of Cardiology, 2015, 66, 2607-2613.	2.8	50
390	The Wearable Cardioverter-Defibrillator inÂNewly Diagnosed Cardiomyopathy. Journal of the American College of Cardiology, 2015, 66, 2614-2617.	2.8	4
391	Left Ventricular Dilatation Increases the Risk of Ventricular Arrhythmias in Patients With Reduced Systolic Function. Journal of the American Heart Association, 2015, 4, e001566.	3.7	27
392	Long-Term Management and Unmet Needs After an Acute Coronary Syndrome Event. American Journal of Cardiology, 2015, 115, 29A-35A.	1.6	2

#	Article	IF	CITATIONS
393	Prevalence and Outcomes of Patients Receiving Implantable Cardioverter-Defibrillators for Primary Prevention Not Based on Guidelines. American Journal of Cardiology, 2015, 115, 1539-1544.	1.6	1
394	Automatic SVM classification of sudden cardiac death and pump failure death from autonomic and repolarization ECG markers. Journal of Electrocardiology, 2015, 48, 551-557.	0.9	32
395	Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis – an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks. BMC Medicine, 2015, 13, 55.	5.5	165
396	Targeting protein tyrosine phosphatase $\ddot{l}f$ after myocardial infarction restores cardiac sympathetic innervation and prevents arrhythmias. Nature Communications, 2015, 6, 6235.	12.8	84
397	Japan Implantable Devices in Coronary Artery Disease (JID AD) study design. Journal of Arrhythmia, 2015, 31, 83-87.	1.2	2
398	The Role of I-123 Metaiodobenzylguanidine Imaging in Management of Patients With Heart Failure. American Journal of Cardiology, 2015, 116, S1-S9.	1.6	6
399	Repeated echocardiography after first ever ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention – is it necessary?. European Heart Journal: Acute Cardiovascular Care, 2015, 4, 528-536.	1.0	21
400	Prognostic Significance of Imaging Myocardial Sympathetic Innervation. Current Cardiology Reports, 2015, 17, 62.	2.9	15
401	Current State of the Art Cardiovascular MR Imaging Techniques for Assessment of Ischemic Heart Disease. Radiologic Clinics of North America, 2015, 53, 335-344.	1.8	9
402	Vagus nerve stimulation reverses ventricular electrophysiological changes induced by hypersympathetic nerve activity. Experimental Physiology, 2015, 100, 239-248.	2.0	22
404	<scp>Frequency</scp> and Implications of Ischemia Prior to Ventricular Tachyarrhythmia in Patients Treated With a Wearable Cardioverter Defibrillator Following Myocardial Infarction. Clinical Cardiology, 2016, 39, 399-405.	1.8	6
405	Mortality pattern and cause of death in a long-term follow-up of patients with STEMI treated with primary PCI. Open Heart, 2016, 3, e000405.	2.3	60
406	Myeloperoxidase Inhibition Improves Ventricular Function and Remodeling AfterÂExperimental Myocardial Infarction. JACC Basic To Translational Science, 2016, 1, 633-643.	4.1	77
407	Quantitative T-wave alternans analysis for sudden cardiac death risk assessment and guiding therapy: answered and unanswered questions. Journal of Electrocardiology, 2016, 49, 429-438.	0.9	6
409	Outcomes of Catheter Ablation of Ventricular Tachycardia in the Setting of Structural Heart Disease. Current Cardiology Reports, 2016, 18, 68.	2.9	10
410	ST-elevation myocardial infarction with reduced left ventricular ejection fraction: Insights into persisting left ventricular dysfunction. A pPCI-registry analysis. International Journal of Cardiology, 2016, 215, 340-345.	1.7	15
411	Predictors of Sudden Cardiac Death in Doberman Pinschers with Dilated Cardiomyopathy. Journal of Veterinary Internal Medicine, 2016, 30, 722-732.	1.6	27
412	Indications and use of the wearable cardiac defibrillator. European Heart Journal, 2016, 38, ehw353.	2.2	13

		CITATION R	EPORT	
#	Article		IF	CITATIONS
413	Adverse Effects of Nonsteroidal Anti-inflammatory Drugs on the Cardiovascular System.	, 2016, , 61-89.		1
414	Time to Reperfusion in ST-Segment Elevation Myocardial Infarction Patients With vs. Wir Pre-Hospital Mobile Telemedicine 12-Lead Electrocardiogram Transmission. Circulation Jo 80, 1624-1633.	thout burnal, 2016,	1.6	42
415	Ramipril attenuates left ventricular remodeling by regulating the expression of activin A- a rat model of heart failure. Scientific Reports, 2016, 6, 33677.	follistatin in	3.3	12
416	Assessment of the longitudinal changes in infarct heterogeneity post myocardial infarcti Cardiovascular Disorders, 2016, 16, 198.	on. BMC	1.7	9
417	The wearable cardioverter defibrillator as a bridge to implantable defibrillator post myoca infarction: what do we know?. Expert Review of Medical Devices, 2016, 13, 627-632.	ardial	2.8	0
418	Time Dependence of VentricularÂTachyarrhythmias AfterÂMyocardial Infarction. JACC: C Electrophysiology, 2016, 2, 565-573.	linical	3.2	0
419	Programmed Ventricular Stimulation to Risk Stratify for Early Cardioverter-Defibrillator Implantation to Prevent Tachyarrhythmias following Acute Myocardial Infarction (PROTE Protocol, Background and Significance. Heart Lung and Circulation, 2016, 25, 1055-106	CT-ICD): Trial 2.	0.4	32
420	Wearable Cardioverter-Defibrillator Therapy for the Prevention of Sudden Cardiac Death. Circulation, 2016, 133, 1715-1727.		1.6	108
421	Epidemiology, Risk Factors, and Outcomes of Out-of-Hospital Cardiac Arrest Caused by S Medicine (United States), 2016, 95, e3107.	Stroke.	1.0	16
422	Myocardial Infarction Causes Transient Cholinergic Transdifferentiation of Cardiac Symp Nerves via gp130. Journal of Neuroscience, 2016, 36, 479-488.	athetic	3.6	46
423	Generation of electrophysiologically functional cardiomyocytes from mouse induced plu stem cells. Stem Cell Research, 2016, 16, 522-530.	ripotent	0.7	14
424	Sudden Cardiac Death After Non–ST-Segment Elevation Acute Coronary Syndrome. JA 2016, 1, 73.	MA Cardiology,	6.1	22
425	Cardioprotective effects of baicalein on heart failure via modulation of Ca2+ handling pr vivo and in vitro. Life Sciences, 2016, 145, 213-223.	oteins in	4.3	46
427	Avoiding Untimely Implantable Cardioverter/Defibrillator Implantation by Intensified Hea Therapy Optimization Supported by the Wearable Cardioverter/Defibrillator—The PROI Journal of the American Heart Association, 2017, 6, .	rt Failure _ONG Study.	3.7	67
429	Identification of the potentially arrhythmogenic substrate in the acute phase of ST-segm myocardial infarction. Heart Rhythm, 2017, 14, 592-598.	ent elevation	0.7	11
430	Correlation between the high-frequency content of the QRS on murine surface electroca and the sympathetic nerves density in left ventricle after myocardial infarction: Experime Journal of Electrocardiology, 2017, 50, 323-331.	rdiogram ental study.	0.9	8
432	Ventricular Tachycardia in Ischemic Heart Disease. Cardiac Electrophysiology Clinics, 201	17, 9, 25-46.	1.7	23
433	Postinfarct Ventricular Arrhythmias. Circulation: Cardiovascular Interventions, 2017, 10,	e004995.	3.9	0

#	Article	IF	CITATIONS
435	Arrhythmic risk stratification in heart failure: Time for the next step?. , 2017, 22, e12430.		22
436	Primary Prevention of Sudden Cardiac Death Early Post-Myocardial Infarction. Circulation: Arrhythmia and Electrophysiology, 2017, 10, .	4.8	21
437	Sudden Cardiac Death Substrate Imaged by Magnetic Resonance Imaging. Circulation: Cardiovascular Imaging, 2017, 10, .	2.6	59
438	Impact and management of left ventricular function on the prognosis of Takotsubo syndrome. European Journal of Clinical Investigation, 2017, 47, 477-485.	3.4	14
439	A real world wearable cardioverter defibrillator experience – Very high appropriate shock rate in ischemic cardiomyopathy patients at a European single-center. Journal of Electrocardiology, 2017, 50, 603-609.	0.9	12
440	Real world utilization and impact of the wearable cardioverter-defibrillator in a community setting. Indian Pacing and Electrophysiology Journal, 2017, 17, 65-69.	0.6	8
441	Sudden Death in End Stage Renal Disease: Comparing Hemodialysis versus Peritoneal Dialysis. Blood Purification, 2017, 44, 77-88.	1.8	22
442	Mild hypothermia preserves myocardial conduction during ischemia by maintaining gap junction intracellular communication and Na+ channel function. American Journal of Physiology - Heart and Circulatory Physiology, 2017, 312, H886-H895.	3.2	11
443	ICD Utilization. JACC: Clinical Electrophysiology, 2017, 3, 299-301.	3.2	0
444	Primary Prevention Implantable Cardiac Defibrillator Trials. Cardiac Electrophysiology Clinics, 2017, 9, 761-773.	1.7	12
445	Update to Practice Standards for Electrocardiographic Monitoring in Hospital Settings: A Scientific Statement From the American Heart Association. Circulation, 2017, 136, e273-e344.	1.6	165
446	Ventricular Tachycardia and Fibrillation in Patients with Structural Heart Disease. Cardiovascular Medicine, 2017, , 191-204.	0.0	1
447	Role of Cardiac Imaging in Evaluating Risk for Sudden Cardiac Death. Cardiac Electrophysiology Clinics, 2017, 9, 639-650.	1.7	8
448	Hypothermia Modulates Arrhythmia Substrates During Different Phases of Resuscitation From Ischemic Cardiac Arrest. Journal of the American Heart Association, 2017, 6, .	3.7	10
450	The wearable cardioverter-defibrillator: current technology and evolving indications. Europace, 2017, 19, 335-345.	1.7	65
451	Contemporary Management of ST-Elevation Myocardial Infarction. Heart Lung and Circulation, 2017, 26, 114-121.	0.4	4
452	Potential roles of the wearable cardioverter-defibrillator in acute phase care of patients at high risk of sudden cardiac death: A single-center Japanese experience. Journal of Cardiology, 2017, 69, 359-363.	1.9	10
453	Coronary ischemia: Global trigger of sudden cardiac death. Heart Rhythm, 2017, 14, 88-89.	0.7	4

#	Article	IF	CITATIONS
454	Reassessment of Cardiac Function and Implantable Cardioverter-Defibrillator Use Among Medicare Patients With Low Ejection Fraction After Myocardial Infarction. Circulation, 2017, 135, 38-47.	1.6	16
455	Incidence and predictors of sudden arrhythmic death or ventricular tachyarrhythmias after acute coronary syndrome: An asian perspective. Heart Rhythm, 2017, 14, 81-87.	0.7	8
456	Management of Arrhythmias in Heart Failure. Journal of Cardiovascular Development and Disease, 2017, 4, 3.	1.6	47
458	Improvement of left ventricular ejection fraction in revascularized postmyocardial patients: indication for statistical fallacy. BMC Research Notes, 2017, 10, 244.	1.4	11
459	Non-Invasive Ventilation in Patients with Heart Failure: A Systematic Review and Meta-Analysis. Arquivos Brasileiros De Cardiologia, 2017, 108, 161-168.	0.8	9
460	Arrhythmias Post Coronary Artery Bypass Surgery. , 0, , .		2
461	Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. European Heart Journal, 2018, 39, 2314-2325.	2.2	186
462	Sudden Death in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 2018, 6, 653-661.	4.1	56
463	Activin A inhibition attenuates sympathetic neural remodeling following myocardial infarction in rats. Molecular Medicine Reports, 2018, 17, 5074-5080.	2.4	7
464	Risk Stratification for Sudden Cardiac Death After Myocardial Infarction. Annual Review of Medicine, 2018, 69, 147-164.	12.2	43
465	The Wearable Cardioverter-Defibrillation. JACC: Clinical Electrophysiology, 2018, 4, 240-242.	3.2	1
466	Sudden cardiac death after acute heart failure hospital admission: insights from ASCENDâ€HF. European Journal of Heart Failure, 2018, 20, 525-532.	7.1	29
467	Sudden cardiac death following admission for acute heart failure: adding insult to injury. European Journal of Heart Failure, 2018, 20, 533-535.	7.1	3
468	Electrophysiology testing for risk stratification of patients with ischaemic cardiomyopathy: a call for action. Europace, 2018, 20, f148-f152.	1.7	9
469	Therapy optimization in patients with heart failure: the role of the wearable cardioverter-defibrillator in a real-world setting. BMC Cardiovascular Disorders, 2018, 18, 52.	1.7	20
470	Learned Helplessness and Depressive Symptoms Following Myocardial Infarction. Clinical Nursing Research, 2018, 27, 597-616.	1.6	20
471	Evaluation of specific neural marker GAP-43 and TH combined with Masson-trichrome staining for forensic autopsy cases with old myocardial infarction. International Journal of Legal Medicine, 2018, 132, 187-195.	2.2	5
472	2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary. Heart Rhythm, 2018, 15, e190-e252.	0.7	448

#	Article	IF	CITATIONS
473	2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Heart Rhythm, 2018, 15, e73-e189.	0.7	262
474	2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary. Journal of the American College of Cardiology, 2018, 72, 1677-1749.	2.8	382
475	2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary. Circulation, 2018, 138, e210-e271.	1.6	250
476	2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Circulation, 2018, 138, e272-e391.	1.6	468
477	Ventricular Arrhythmia Occurrence and Compliance in Patients Treated With the Wearable Cardioverter Defibrillator Following Percutaneous Coronary Intervention. Heart Lung and Circulation, 2018, 27, 984-988.	0.4	7
478	Experience With Wearable Cardioverter-Defibrillators at 2ÂAcademicÂMedical Centers. JACC: Clinical Electrophysiology, 2018, 4, 231-239.	3.2	9
479	Non-ST-Elevation Acute Coronary Syndrome Prognosis. , 2018, , 502-521.		1
480	OBSOLETE: STEMI: Prognosis. , 2018, , .		0
481	Prevention of Sudden Cardiac Death. , 2018, , 321-336.		0
483	OBSOLETE: Ventricular Tachycardia in Ischemic and Dilated Cardiomyopathy: Mechanisms and Diagnosis. , 2018, , .		0
484	OBSOLETE: Non-ST-Elevation Acute Coronary Syndrome Prognosis. , 2018, , .		0
486	Electrocardiographic Monitoring Strategies (Holter, Implantable Loop Recorder, in Between). , 2018, , 197-210.		1
487	Knowledge and Insights Vested in Us by the VEST. Circulation, 2018, 138, 2735-2737.	1.6	2
488	Ventricular Tachycardia in Ischemic and Dilated Cardiomyopathy: Mechanisms and Diagnosis. , 2018, , 690-699.		0
489	Another Shock for Sudden Death Prevention after Myocardial Infarction. New England Journal of Medicine, 2018, 379, 1274-1275.	27.0	11
490	Wearable Cardioverter–Defibrillator after Myocardial Infarction. New England Journal of Medicine, 2018, 379, 1205-1215.	27.0	229
491	T1 Mapping in Peri-infarct Injury in Ischemic Cardiomyopathy. , 2018, , 77-86.		0
492	Renal Denervation Reduced Ventricular Arrhythmia After Myocardial Infarction by Inhibiting Sympathetic Activity and Remodeling. Journal of the American Heart Association, 2018, 7, e009938.	3.7	31

#	Article	IF	CITATIONS
493	Role of the Wearable Defibrillator in Newly Diagnosed Heart Failure. Current Heart Failure Reports, 2018, 15, 368-375.	3.3	12
494	T1-Mapping in Myocardial Disease. , 2018, , .		1
495	Electrocardiogram as a predictor of sudden cardiac death in middle-aged subjects without a known cardiac disease. IJC Heart and Vasculature, 2018, 20, 50-55.	1.1	10
496	Modes and timing of death in 66 252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials. European Heart Journal, 2018, 39, 3810-3820.	2.2	28
497	Chronic median nerve modulation reduces ventricular arrhythmia and improves ventricular function in a postmyocardial infarction rabbit model. Cardiovascular Therapeutics, 2018, 36, e12437.	2.5	1
498	Right Ventricular Dysfunction and Long-Term Risk of Sudden Cardiac Death in Patients With and Without Severe Left Ventricular Dysfunction. Circulation: Arrhythmia and Electrophysiology, 2018, 11, e006091.	4.8	34
499	Evaluation of cardiac arrhythmic risks using a rabbit model of left ventricular systolic dysfunction. European Journal of Pharmacology, 2018, 832, 145-155.	3.5	18
500	Ventricular tachycardia-inducibility predicts arrhythmic events in post-myocardial infarction patients with low ejection fraction. A systematic review and meta-analysis. IJC Heart and Vasculature, 2018, 20, 7-13.	1.1	7
501	Left ventricular sphericity index analysis for the prediction of appropriate implantable cardioverterâ€defibrillator therapy. PACE - Pacing and Clinical Electrophysiology, 2018, 41, 1192-1196.	1.2	4
503	Clinical Usefulness of Wearable Cardioverter Defibrillator (WCD) and Current Understanding of Its Clinical Indication in Japan. Circulation Journal, 2018, 82, 1481-1486.	1.6	12
504	STEMI: Prognosis. , 2018, , 489-498.		1
505	2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Journal of the American College of Cardiology, 2018, 72, e91-e220.	2.8	991
506	Recent Updates in the Role of Wearable Cardioverter Defibrillator for Prevention of Sudden Cardiac Death. Current Treatment Options in Cardiovascular Medicine, 2019, 21, 49.	0.9	1
509	Sudden cardiac death: an update. Internal Medicine Journal, 2019, 49, 826-833.	0.8	28
510	An Automated Strategy for Early Risk Identification of Sudden Cardiac Death by Using Machine Learning Approach on Measurable Arrhythmic Risk Markers. IEEE Access, 2019, 7, 94701-94716.	4.2	67
511	2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias. Europace, 2019, 21, 1143-1144.	1.7	245
512	Cardiovascular magnetic resonance: A promising method for detecting myocardial scar in patients with cardiac implantable devices. International Journal of Cardiology, 2019, 292, 271.	1.7	0
513	Cardiac arrhythmias in the emergency settings of acute coronary syndrome and revascularization: an European Heart Rhythm Association (EHRA) consensus document, endorsed by the European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Acute Cardiovascular Care Association (ACCA). Europace, 2019, 21, 1603-1604.	1.7	61

#	Article	IF	CITATIONS
514	Translational Models of Arrhythmia Mechanisms and Susceptibility: Success and Challenges of Modeling Human Disease. Frontiers in Cardiovascular Medicine, 2019, 6, 135.	2.4	13
515	Normal Left and Right Ventricular Volume and Function. Contemporary Cardiology, 2019, , 77-86.	0.1	0
516	The wearable cardioverter-defibrillator vest: Indications and ongoing questions. Progress in Cardiovascular Diseases, 2019, 62, 256-264.	3.1	3
517	Physical activity and risk of instant and 28-day case-fatality in myocardial infarction. PLoS ONE, 2019, 14, e0217398.	2.5	6
518	Early recurrent arrhythmias after out-of-hospital cardiac arrest associated with obstructive coronary artery disease: Analysis of the PROCAT registry. Resuscitation, 2019, 141, 81-87.	3.0	3
519	Biomarker of Collagen Turnover (Câ€Terminal Telopeptide) andÂPrognosis in Patients With Nonâ€STâ€Elevation Acute CoronaryÂSyndromes. Journal of the American Heart Association, 2019, 8, e011444.	3.7	11
520	Beyond pharmacological treatment: an insight into therapies that target specific aspects of heart failure pathophysiology. Lancet, The, 2019, 393, 1045-1055.	13.7	48
521	Nine contemporary therapeutic directions in heart failure. Heart Asia, 2019, 11, e011150.	1.1	2
522	Treatment with mononuclear cell populations improves post-infarction cardiac function but does not reduce arrhythmia susceptibility. PLoS ONE, 2019, 14, e0208301.	2.5	1
523	Efficacy of an implantable cardioverter-defibrillator in patients with diabetes and heart failure and reduced ejection fraction. Clinical Research in Cardiology, 2019, 108, 868-877.	3.3	11
524	Social Support, Self-Efficacy, and Helplessness Following Myocardial Infarctions. Critical Care Nursing Quarterly, 2019, 42, 246-255.	0.8	9
525	Establishment of a predictive model for inpatient sudden cardiac death in a Chinese cardiac department population. Chinese Medical Journal, 2019, 132, 17-24.	2.3	1
526	Sudden Death Risk-Stratification in 2018–2019: The Old and the New. Heart Lung and Circulation, 2019, 28, 57-64.	0.4	24
527	Adjunctive Pharmacologic Therapies in Acute Myocardial Infarction. , 2019, , 117-138.e7.		2
528	Impact of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with heart failure and left-ventricular systolic dysfunction: an individual patient-level meta-analysis of three randomized-controlled trials. Clinical Research in Cardiology, 2019, 108, 477-486.	3.3	64
529	2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias. Heart Rhythm, 2020, 17, e2-e154.	0.7	184
530	2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias: Executive summary. Heart Rhythm, 2020, 17, e155-e205.	0.7	67
531	Incidence and Predictors of Sudden Cardiac Death After a Major Non-Fatal Cardiovascular Event. Heart Lung and Circulation, 2020, 29, 679-686.	0.4	1

#	Article	IF	CITATIONS
532	Sub-acute cardiac magnetic resonance to predict irreversible reduction in left ventricular ejection fraction after ST-segment elevation myocardial infarction: A DANAMI-3 sub-study. International Journal of Cardiology, 2020, 301, 215-219.	1.7	3
533	Follow-Up After Myocardial Infarction toÂExplore the Stability of Arrhythmogenic Substrate. JACC: Clinical Electrophysiology, 2020, 6, 207-218.	3.2	16
534	Long-Term Outcome of the Randomized DAPA Trial. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008484.	4.8	18
535	Comparison of Mortality and Readmission in Non-Ischemic Versus Ischemic Cardiomyopathy After Implantable Cardioverter-Defibrillator Implantation. American Journal of Cardiology, 2020, 133, 116-125.	1.6	13
536	Outcomes in non-ST-segment elevation myocardial infarction patients according to heart failure at admission: Insights from a large trial with systematic early invasive strategy. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 736-745.	1.0	3
537	A CNT-PDMS wearable device for simultaneous measurement of wrist pulse pressure and cardiac electrical activity. Materials Science and Engineering C, 2020, 117, 111345.	7.3	30
538	Arrhythmias of subacute phase of myocardial infarction. , 2020, , 571-582.		0
539	Sex-specific mechanisms of sudden cardiac death. , 2020, , 767-774.		0
540	The Wearable Cardioverter-Defibrillator. , 0, , .		0
541	Adrenergic supersensitivity and impaired neural control of cardiac electrophysiology following regional cardiac sympathetic nerve loss. Scientific Reports, 2020, 10, 18801.	3.3	20
542	Incidence and Predictors of Out-of-Hospital Cardiac Arrest Within 90 Days After Myocardial Infarction. Journal of the American College of Cardiology, 2020, 76, 2926-2936.	2.8	23
543	Early Post-Infarction Survival in the Modern Era. Journal of the American College of Cardiology, 2020, 76, 2937-2939.	2.8	0
544	Collaborative care for the wearable cardioverter defibrillator patient: Getting the patient and medical team "vested and active― Journal of Cardiovascular Electrophysiology, 2020, 31, 2509-2515.	1.7	4
545	Macrophage-mediated regulation of catecholamines in sympathetic neural remodeling after myocardial infarction. Basic Research in Cardiology, 2020, 115, 56.	5.9	24
546	Sex Influence on Heart Failure Prognosis. Frontiers in Cardiovascular Medicine, 2020, 7, 616273.	2.4	20
547	Mode of Death Among Japanese Adults With Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction. JAMA Network Open, 2020, 3, e204296.	5.9	32
548	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population. Europace, 2020 22 1147-1148	1.7	62
549	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population. Journal of Arrhythmia. 2020. 36. 553-607.	1.2	40

#	Article	IF	Citations
550	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population. Heart Rhythm, 2020, 17, e269-e316.	0.7	15
551	Established and Emerging Pharmacological Therapies for Post-Myocardial Infarction Patients with Heart Failure: a Review of the Evidence. Cardiovascular Drugs and Therapy, 2020, 34, 723-735.	2.6	11
552	Ventricular arrhythmias and ARNI: is it time to reappraise their management in the light of new evidence?. Heart Failure Reviews, 2020, , 1.	3.9	9
553	Cardiac remodeling after large ST-elevation myocardial infarction in the current therapeutic era. American Heart Journal, 2020, 223, 87-97.	2.7	17
554	The Wearable Cardioverter-Defibrillator: Experience in 153 Patients and a Long-Term Follow-Up. Journal of Clinical Medicine, 2020, 9, 893.	2.4	13
555	2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias. Journal of Interventional Cardiac Electrophysiology, 2020, 59, 145-298.	1.3	19
556	2019 <scp>HRS</scp> / <scp>EHRA</scp> / <scp>APHRS</scp> / <scp>LAHRS</scp> expert consensus statement on catheter ablation of ventricular arrhythmias: Executive summary. Journal of Arrhythmia, 2020, 36, 1-58.	1.2	20
557	Patient selection for wearable cardioverter defibrillator therapy after myocardial infarction: How can we incorporate compliance into decisionâ€making?. Journal of Cardiovascular Electrophysiology, 2020, 31, 1019-1021.	1.7	3
558	Impact of wearable cardioverterâ€defibrillator compliance on outcomes in the VEST trial: Asâ€treated and perâ€protocol analyses. Journal of Cardiovascular Electrophysiology, 2020, 31, 1009-1018.	1.7	52
559	Predictors of sudden cardiac death in highâ€risk patients following a myocardial infarction. European Journal of Heart Failure, 2020, 22, 848-855.	7.1	14
560	Sudden cardiac death after myocardial infarction. European Journal of Heart Failure, 2020, 22, 856-858.	7.1	8
561	2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias: executive summary. Europace, 2020, 22, 450-495.	1.7	29
562	2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias: Executive summary. Journal of Interventional Cardiac Electrophysiology, 2020, 59, 81-133.	1.3	9
563	Butyrate improves cardiac function and sympathetic neural remodeling following myocardial infarction in rats. Canadian Journal of Physiology and Pharmacology, 2020, 98, 391-399.	1.4	28
564	Indications and Use of the Wearable Cardioverter-Defibrillator. , 2021, , 265-273.		0
565	Risk of inâ€hospital lifeâ€threatening ventricular arrhythmia or death after STâ€elevation myocardial infarction vs. the Takotsubo syndrome. ESC Heart Failure, 2021, 8, 1314-1323.	3.1	5
566	Prognostic impact of mean heart rate by Holter monitoring on long-term outcome in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention. Clinical Research in Cardiology, 2021, 110, 1439-1449.	3.3	2
567	Tâ€wave heterogeneity in standard resting 12â€lead ECGs is associated with 90â€day cardiac mortality in women following emergency department admission: A nested case–control study. Annals of Noninvasive Electrocardiology, 2021, 26, e12826.	1.1	5

#	Article	IF	CITATIONS
568	Sudden death and its predictors in myocardial infarction survivors in an Indian population. Indian Pacing and Electrophysiology Journal, 2021, 21, 82-87.	0.6	6
569	Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data. Lancet, The, 2021, 397, 1085-1094.	13.7	146
570	Human biventricular electromechanical simulations on the progression of electrocardiographic and mechanical abnormalities in post-myocardial infarction. Europace, 2021, 23, i143-i152.	1.7	15
571	Dynamic changes in cardiovascular and systemic parameters prior to sudden cardiac death in heart failure with reduced ejection fraction: a <scp>PARADIGMâ€HF</scp> analysis. European Journal of Heart Failure, 2021, 23, 1346-1356.	7.1	11
572	Early ICD implantation in cardiac arrest survivors with acute coronary syndrome – predictors of implantation, ICD-therapy and long-term survival. Scandinavian Cardiovascular Journal, 2021, 55, 205-212.	1.2	4
573	Lack of Macrophage Migration Inhibitory Factor Reduces Susceptibility to Ventricular Arrhythmias During the Acute Phase of Myocardial Infarction. Journal of Inflammation Research, 2021, Volume 14, 1297-1311.	3.5	3
574	Looking forward and backward for sudden death risk: competing risk is everywhere. European Journal of Heart Failure, 2021, 23, 1357-1360.	7.1	0
575	Sudden Cardiac Death in Patients with Heart Disease and Preserved Systolic Function: Current Options for Risk Stratification. Journal of Clinical Medicine, 2021, 10, 1823.	2.4	12
576	Vagus Nerve Stimulation in Early Stage of Acute Myocardial Infarction Prevent Ventricular Arrhythmias and Cardiac Remodeling. Frontiers in Cardiovascular Medicine, 2021, 8, 648910.	2.4	13
577	Prognosis of the non-ST elevation myocardial infarction complicated with early ventricular fibrillation at higher age. GeroScience, 2021, 43, 2561-2571.	4.6	0
578	Primary Prevention Implantable Cardioverter-Defibrillator Therapy in Heart Failure with Recovered Ejection Fraction. Journal of Cardiac Failure, 2021, 27, 585-596.	1.7	1
579	Effective treatment of electrical storm by a wearable cardioverter defibrillator in a patient with severely impaired left ventricular function after myocardial infarction: a case report. Journal of Medical Case Reports, 2021, 15, 243.	0.8	3
580	JCS/JHRS 2019 Guideline on Non-Pharmacotherapy of Cardiac Arrhythmias. Circulation Journal, 2021, 85, 1104-1244.	1.6	77
581	The AED Project: Multiorganization Collaboration to Streamline Automatic External Defibrillator Data in Out-of-Hospital Cardiac Arrests. CJC Open, 2021, 3, 695-702.	1.5	0
582	Factors that predict ventricular arrhythmias in the late phase after acute myocardial infarction. ESC Heart Failure, 2021, 8, 4152-4160.	3.1	9
583	JCS/JHRS 2019 guideline on nonâ€pharmacotherapy of cardiac arrhythmias. Journal of Arrhythmia, 2021, 37, 709-870.	1.2	91
584	Wearable cardioverter-defibrillators after myocardial infarction: a review of its clinical utility and unmet needs in current clinical practice. Cardiovascular Intervention and Therapeutics, 2022, 37, 53-59.	2.3	4
585	One‥ear Landmark Analysis of the Effect of Betaâ€Blocker Dose on Survival After Acute Myocardial Infarction. Journal of the American Heart Association, 2021, 10, e019017.	3.7	16

#	Article	IF	CITATIONS
586	Clinical conditions and echocardiographic parameters associated with mortality in COVIDâ€19. European Journal of Clinical Investigation, 2021, 51, e13638.	3.4	26
587	Predictors of Sudden Cardiac Arrest Among Patients With Postâ€Myocardial Infarction Ejection Fraction Greater Than 35%. Journal of the American Heart Association, 2021, 10, e020993.	3.7	4
588	Health-related quality of life in men and women who experienced cardiovascular diseases: Tehran Lipid and Glucose Study. Health and Quality of Life Outcomes, 2021, 19, 225.	2.4	5
589	Targeting Parasympathetic Activity to Improve Autonomic Tone & Clinical Outcomes. Physiology, 2021, ,	3.1	3
590	Spectrum of clinical applications of interlead ECG heterogeneity assessment: From myocardial ischemia detection to sudden cardiac death risk stratification. Annals of Noninvasive Electrocardiology, 2021, 26, e12894.	1.1	11
591	Ventricular Arrhythmias in Ischemic Cardiomyopathy—New Avenues for Mechanism-Guided Treatment. Cells, 2021, 10, 2629.	4.1	21
592	Predicting Sudden Cardiac Death After Myocardial Infarction. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e009422.	4.8	4
593	Survival Predictors of Heart Rate Variability After Myocardial Infarction With and Without Low Left Ventricular Ejection Fraction. Frontiers in Neuroscience, 2021, 15, 610955.	2.8	21
594	Prognosis and clinical characteristics of patients with early ventricular fibrillation in the 6-week guideline-offered time period: is it safe to wait 6 weeks with the assessment? (results from the) Tj ETQq0 0 0 rgBT	⊺∥ ಖø erlocl	۲ 10 Tf 50 41
595	Normal Left and Right Ventricular Volume and Function. , 2008, , 113-121.		1
596	Cardiac Arrest and Sudden Cardiac Death. , 2012, , 845-884.		33
597	Ventricular tachycardia and sudden cardiac death. Mayo Clinic Proceedings, 2009, 84, 289-97.	3.0	52
598	Implantable cardioverter defibrillators after acute myocardial infarction. BMJ: British Medical Journal, 2010, 341, c5741-c5741.	2.3	2
599	Diabetes increases mortality after myocardial infarction by oxidizing CaMKII. Journal of Clinical Investigation, 2013, 123, 1262-1274.	8.2	203
600	Wearable Cardioverter Defibrillator ― Initial Experience in the Outpatient Setting in Japan ―. Circulation Reports, 2020, 2, 137-142.	1.0	1

800	Reports, 2020, 2, 137-142.	1.0	1
601	Echocardiographic global longitudinal strain is associated with infarct size assessed by cardiac magnetic resonance in acute myocardial infarction. Echo Research and Practice, 2019, 6, 81-89.	2.5	14
602	Use and Abuse of Internal Cardioverter Defibrillators for Primary Prevention. Arrhythmia and Electrophysiology Review, 2012, 1, 46.	2.4	4
604	Risk Stratification of Sudden Cardiac Death After Acute Myocardial Infarction. Journal of Innovations in Cardiac Rhythm Management, 2018, 9, 3035-3049.	0.5	11

#		IE	CITATIONS
# 605	Wearable Cardioverter-defibrillators for the Prevention of Sudden Cardiac Death: A Meta-analysis. Journal of Innovations in Cardiac Rhythm Management, 2018, 9, 3151-3162.	0.5	17
606	CHRONIC KIDNEY DISEASE AND ARRHYTHMIAS: CONCLUSIONS FROM A KIDNEY DISEASE: IMPROVING GLOBAL OUTCOMES (KDIGO) CONTROVERSIES CONFERENCE. Nephrology (Saint-Petersburg), 2019, 23, 18-40.	0.4	5
607	Value of The Wearable Cardioverter Defibrillator (WCD) as a Bridging-Therapy before Implantation of a Cardioverter Defibrillator (ICD). Journal of Atrial Fibrillation, 2016, 8, 1247.	0.5	1
608	The Wearable Cardioverter/Defibrillator - Toy Or Tool?. Journal of Atrial Fibrillation, 2016, 8, 1367.	0.5	14
609	An Old Idea for a New Age. American Journal of Critical Care, 2006, 15, 118-120.	1.6	3
610	Recognizing and Managing Asymptomatic Left Ventricular Dysfunction. Critical Care Nurse, 2008, 28, 20-37.	1.0	19
611	Risk factors for sudden cardiac death to determine high risk patients in specific patient populations that may benefit from a wearable defibrillator. World Journal of Cardiology, 2019, 11, 103-119.	1.5	4
612	Wearable cardioverter defibrillator: Bridge or alternative to implantation?. World Journal of Cardiology, 2017, 9, 531.	1.5	11
613	Graft Strategy for Coronary Artery Bypass Grafting in Patients with Severe Left Ventricular Dysfunction. Korean Journal of Thoracic and Cardiovascular Surgery, 2019, 52, 16-24.	0.6	2
614	Ultrasonic biomechanics method for vortex and wall motion of left ventricle: a phantom and in vivo study. BMC Cardiovascular Disorders, 2021, 21, 516.	1.7	0
615	Evaluation of potential underuse of cardiac resynchronization therapy for heart failure with reduced ejection fraction. Journal of Arrhythmia, 2021, 37, 1532-1536.	1.2	0
616	Real-world experience with the wearable cardioverter defibrillator: clinical effectiveness and wear-time adherence in patients at high risk for sudden cardiac death. Herzschrittmachertherapie Und Elektrophysiologie, 2021, , 1.	0.8	0
617	Ventricular Arrhythmias in Patients After Myocardial Infarction. , 2008, , 190-203.		0
618	Sudden Cardiac Death in Advanced Ischemic Heart Disease. , 2009, , 37-47.		0
619	Implantable Cardioverter-Defibrillators. , 2010, , 155-184.		1
621	Assessment of Myocardial Infarction by Cardiac Magnetic Resonance Imaging and Long-Term Mortality. Arquivos Brasileiros De Cardiologia, 2014, 104, 159-68.	0.8	3
622	STUDY OF ARRHYTHMIAS IN ACUTE INFERIOR WALL MYOCARDIAL INFARCTION. Journal of Evidence Based Medicine and Healthcare, 2014, 1, 533-538.	0.0	0
623	Overview of Recent Findings on Prevention of Sudden Cardiac Death. Japanese Journal of Electrocardiology, 2015, 35, 205-212.	0.0	0

#	Article	IF	CITATIONS
624	Clinical Significance of Non-invasive Magnetic Resonance Imaging to Identify High-risk Coronary Plaques as Potential Biomarkers for Preemptive Medicine. Journal of the Japanese Coronary Association, 2015, 21, 278-286.	0.0	1
625	Principles of Primary and Secondary Prevention of Cardiovascular Disease. , 2015, , 1627-1664.		0

626 å¿f臓çªç"¶æ»ã®é«~ãfªã,¹ã,⁻ç—‡ä¾<ã«å⁻¾ã™ã,<ç€ç""型自å<•é™♥°å‹•å™ïã®åŸä½;ç""経é"". Journal of JCSœardiolog0sts, 2015,

628	Can We Select Patients for Prophylactic VT Ablation?. Arrhythmia and Electrophysiology Review, 2017, 6, 223.	2.4	0
629	Arrhythmias in Cardiomyopathy. , 2017, , 285-321.		0
631	OBSOLETE: Electrocardiographic Monitoring Strategies (Holter, Implantable Loop Recorder, in) Tj ETQq1 1 0.784	4314 rgBT	Overlock 1
632	Wearable Cardioverter-Defibrillators. , 2019, , 27-38.		0
633	Le gilet défibrillantÂ: life-vest. Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique, 2019, 2019, 23-27.	0.0	0
634	Neuromodulation of Cardiac Repolarization and Arrhythmogenesis. , 2020, , 49-76.		0
635	Non-fatal cardiovascular events preceding sudden cardiac death in patients with an acute myocardial infarction complicated by heart failure: insights from the high-risk myocardial infarction database. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 127-131.	1.0	3
636	Noninvasive Risk Stratification for Sudden Cardiac Death. , 2020, , 377-391.		0
638	Risk of death and recurrent ventricular arrhythmias in survivors of cardiac arrest concurrent with acute myocardial infarction. Indian Pacing and Electrophysiology Journal, 2008, 8, 5-13.	0.6	3
640	Nitric Oxide Synthase 1 Adaptor Protein, an Emerging New Genetic Marker for QT Prolongation and Sudden Cardiac Death. Acta Cardiologica Sinica, 2013, 29, 217-25.	0.2	11
641	Practice viewpoints: AICD, who and when?. Heart Asia, 2009, 1, 47-9.	1.1	0
642	Mortality and Costs Associated with Wearable Cardioverter-defibrillators after Acute Myocardial Infarction: A Retrospective Cohort Analysis of Medicare Claims Data. Journal of Innovations in Cardiac Rhythm Management, 2019, 10, 3866-3873.	0.5	1
643	Wearable Cardioverter-Defibrillator Used as a Telemonitoring System in a Real-Life Heart Failure Unit Setting. Journal of Clinical Medicine, 2021, 10, 5435.	2.4	3
644	Transcription factor Meis1 act as a new regulator of ischemic arrhythmias in mice. Journal of Advanced Research, 2022, 39, 275-289.	9.5	2
645	Sudden Cardiac Arrest During the Immediate Revascularization Period in Patients With Non-ST Elevation Myocardial Infarction: A Case Series. Cardiovascular Revascularization Medicine, 2022, 40, 332-336.	0.8	1

#	Article	IF	CITATIONS
647	Incidence and predictors of sudden cardiac arrest in the immediate post-percutaneous coronary intervention period for ST-elevation myocardial infarction: a single-center study. Coronary Artery Disease, 2022, 33, 261-268.	0.7	2
648	Fighting against sudden cardiac death: need for a paradigm shift—Adding near-term prevention and pre-emptive action to long-term prevention. European Heart Journal, 2022, 43, 1457-1464.	2.2	24
649	Cardiovascular Events and Longâ€Term Risk of Sudden Death Among Stabilized Patients After Acute Coronary Syndrome: Insights From IMPROVEâ€IT. Journal of the American Heart Association, 2022, 11, e022733.	3.7	4
650	Real life experience with the wearable cardioverter-defibrillator in an international multicenter Registry. Scientific Reports, 2022, 12, 3203.	3.3	5
652	Reduced Left Ventricular Ejection Fraction Is a Risk for Sudden Cardiac Death in the Early Period After Hospital Discharge in Patients With Acute Myocardial Infarction. Circulation Journal, 2022, 86, 1490-1498.	1.6	4
653	Prognostic Outcomes in Acute Myocardial Infarction Patients Without Standard Modifiable Risk Factors: A Multiethnic Study of 8,680 Asian Patients. Frontiers in Cardiovascular Medicine, 2022, 9, 869168.	2.4	24
654	Sudden cardiac death while waiting: do we need the wearable cardioverter-defibrillator?. Clinical Research in Cardiology, 2022, 111, 1189-1197.	3.3	2
655	The value of wearable cardioverter defibrillator in adult patients with recent myocardial infarction: Economic and clinical implications from a health technology assessment perspective. International Journal of Cardiology, 2022, 356, 12-18.	1.7	6
656	Friend or foe? Unraveling the complex roles of protein tyrosine phosphatases in cardiac disease and development. Cellular Signalling, 2022, 93, 110297.	3.6	1
657	When is a wearable defibrillator indicated?. Expert Review of Medical Devices, 2021, 18, 51-56.	2.8	3
658	The role of FGF21 in the pathogenesis of cardiovascular disease. Chinese Medical Journal, 2021, 134, 2931-2943.	2.3	25
663	Identifying high risk patients post myocardial infarction with reduced left ventricular function using loop recorders INSPIRE-ELR clinical study. Indian Heart Journal, 2022, , .	0.5	1
664	Causal Relationship of Coronary Artery Calcium on Myocardial Infarction and Preventive Effect of Antiplatelet Therapy. Frontiers in Cardiovascular Medicine, 2022, 9, 871267.	2.4	2
665	Surveillance of Arrhythmia in Patients After Myocardial Infarction Using Wearable Electrocardiogram Patch Devices: Prospective Cohort Study. JMIR Cardio, 2022, 6, e35615.	1.7	0
666	Sodium Glucose Cotransporter-2 Inhibition for Acute Myocardial Infarction. Journal of the American College of Cardiology, 2022, 79, 2058-2068.	2.8	41
668	Neutrophils incite and macrophages avert electrical storm after myocardial infarction. , 2022, 1, 649-664.		33
669	Primary Prevention Implantable Cardioverter-Defibrillators in Ischemic Cardiomyopathy. Current Treatment Options in Cardiovascular Medicine, 2022, 24, 123-136.	0.9	0
671	Incidence, Characteristics, and Outcomes of Ventricular Fibrillation Complicating Acute Myocardial Infarction in Women Admitted Alive in the Hospital. Journal of the American Heart Association, 2022,	3.7	7

#	Article	IF	CITATIONS
672	2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. European Heart Journal, 2022, 43, 3997-4126.	2.2	733
673	Polygenic Risk Score Predicts Sudden Death in Patients With Coronary Disease and Preserved Systolic Function. Journal of the American College of Cardiology, 2022, 80, 873-883.	2.8	8
674	Long-term outcomes in acute coronary syndrome patients without standard modifiable risk factors: a multi-ethnic retrospective cohort study Of 5400 asian patients. Journal of Thrombosis and Thrombolysis, 2022, 54, 569-578.	2.1	11
675	From evidence-based medicine to digital twin technology for predicting ventricular tachycardia in ischaemic cardiomyopathy. Journal of the Royal Society Interface, 2022, 19, .	3.4	8
676	Higher mortality in acute coronary syndrome patients without standard modifiable risk factors: Results from a global meta-analysis of 1,285,722 patients. International Journal of Cardiology, 2023, 371, 432-440.	1.7	30
677	Improving Primary Prevention of SCD With ICDs in Asia. JACC Asia, 2022, , .	1.5	0
678	Incidence of sudden cardiac arrest and sudden cardiac death after unstable angina pectoris and myocardial infarction. American Heart Journal, 2023, 257, 9-19.	2.7	8
679	Prognostic Implications of Left Ventricular Ejection Fraction and Left Ventricular End-Diastolic Diameter on Clinical Outcomes in Patients with ICD. Journal of Cardiovascular Development and Disease, 2022, 9, 421.	1.6	0
680	Effects of Cardiac Stem Cell on Postinfarction Arrhythmogenic Substrate. International Journal of Molecular Sciences, 2022, 23, 16211.	4.1	1
681	Eurasian association of cardiology (EAC) guidelines for the prevention and treatment of ventricular heart rhythm disorders and prevention of sudden cardiac death (2022). Eurasian Heart Journal, 2022, , 6-67.	0.8	1
682	Median nerve stimulation elevates ventricular fibrillation threshold via the cholinergic anti-inflammatory pathway in myocardial infarction canine model. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	0
683	Continuous <scp>multiâ€day</scp> tracking of <scp>postâ€myocardial</scp> infarction recovery of cardiac electrical stability and autonomic tone using electrocardiogram patch monitors. Annals of Noninvasive Electrocardiology, 2023, 28, .	1.1	0
684	Scar border zone mass and presence of border zone channels assessed with cardiac magnetic resonance imaging are associated with ventricular arrhythmia in patients with ST-segment elevation myocardial infarction. Europace, 2023, 25, 978-988.	1.7	6
685	Autonomic nervous system and cardiac neuro-signaling pathway modulation in cardiovascular disorders and Alzheimer's disease. Frontiers in Physiology, 0, 14, .	2.8	9
686	Mitochondrial miRNA as epigenomic signatures: Visualizing aging-associated heart diseases through a new lens. Ageing Research Reviews, 2023, 86, 101882.	10.9	3
687	Beta-blockers in the prevention and treatment of ischemic heart disease: Evidence and clinical practice. Heart Views, 2023, 24, 41.	0.2	0
688	Implantable Cardioverter-Defibrillator forÂPrimary Prevention in Asia. JACC Asia, 2023, , .	1.5	0
689	Sudden Cardiac Death in Ischaemic Cardiomyopathy and the Primary Prevention ICD: Time for a More a Personalised Approach?. Interventional Cardiology Review, 0, 18, .	1.6	0

#	Article	IF	CITATIONS
690	Characteristics and outcome of wearable cardioverterâ€defibrillator therapy stratified by gender: Insights from a multicenter international registry. Journal of Cardiovascular Electrophysiology, 2023, 34, 1502-1505.	1.7	0
691	Pathophysiology of Ischemic Syndromes in Coronary Artery Disease. , 2023, , 67-81.		0
692	ANMCO position paper: guide to the appropriate use of the wearable cardioverter defibrillator in clinical practice for patients at high transient risk of sudden cardiac death. European Heart Journal Supplements, 2023, 25, D294-D311.	0.1	1
693	Assessing physical activity with the wearable cardioverter defibrillator in patients with newly diagnosed heart failure. Frontiers in Cardiovascular Medicine, 0, 10, .	2.4	1
694	Loss of chondroitin sulfate proteoglycan sulfation allows delayed sympathetic reinnervation after cardiac ischemia–reperfusion. Physiological Reports, 2023, 11, .	1.7	3
695	RyR2 inhibition with dantrolene is antiarrhythmic, prevents further pathological remodeling, and improves cardiac function in chronic ischemic heart disease. Journal of Molecular and Cellular Cardiology, 2023, 181, 67-78.	1.9	4
696	Predictors for early cardiac death after discharge from successfully treated acute myocardial infarction. Frontiers in Medicine, 0, 10, .	2.6	2
697	Mortality in Patients Hospitalized With Acute Myocardial Infarction Without Standard Modifiable Risk Factors: The ARIC Study Community Surveillance. Journal of the American Heart Association, 2023, 12, .	3.7	1
698	Heterogeneity of Repolarization and Cell-Cell Variability of Cardiomyocyte Remodeling Within the Myocardial Infarction Border Zone Contribute to Arrhythmia Susceptibility. Circulation: Arrhythmia and Electrophysiology, 2023, 16, .	4.8	2
699	Biological Modification of Arrhythmogenic Substrates by Cell-Free Therapeutics. Heart Lung and Circulation, 2023, , .	0.4	1
700	Wearable Cardioverter Defibrillator Shortens the Lengths of Stay in Patients with Left Ventricular Dysfunction after Myocardial Infarction: A Single-Centre Real-World Experience. Journal of Clinical Medicine, 2023, 12, 4884.	2.4	0
703	The Lancet Commission to reduce the global burden of sudden cardiac death: a call for multidisciplinary action. Lancet, The, 2023, 402, 883-936.	13.7	14
704	Prevention of Early Sudden Cardiac Death after Myocardial Infarction Using the Wearable Cardioverter Defibrillator—Results from a Real-World Cohort. Journal of Clinical Medicine, 2023, 12, 5029.	2.4	1
705	Heart rate reactivity mediates the relationship between trait gratitude and acute myocardial infarction. Biological Psychology, 2023, 183, 108663.	2.2	0
706	Myocardial scarring and recurrence of ventricular arrhythmia in patients surviving an outâ€ofâ€hospital cardiac arrest. Journal of Cardiovascular Electrophysiology, 2023, 34, 2286-2295.	1.7	0
707	JCS/JHRS 2022 Guideline on Diagnosis and Risk Assessment of Arrhythmia. Circulation Journal, 2023, , .	1.6	5
708	Prognostic significance of the Holterâ€derived Tâ€wave variability in patients with ventricular tachyarrhythmias complicating acute coronary syndrome— <scp>TWIST</scp> study. Annals of Noninvasive Electrocardiology, 0, , .	1.1	0
709	Canadian Cardiovascular Society 2023 Guidelines on the Fitness to Drive. Canadian Journal of Cardiology, 2023, , .	1.7	0

#	Article	IF	Citations
710	Sex differences in ventricular arrhythmia, atrial fibrillation and atrioventricular block complicating acute myocardial infarction. Frontiers in Cardiovascular Medicine, 0, 10, .	2.4	0
711	Dynamic electrocardiogram changes are a novel risk marker for sudden cardiac death. European Heart Journal, 2024, 45, 809-819.	2.2	0
712	Ischemia-reperfusion myocardial infarction induces remodeling of left cardiac-projecting stellate ganglia neurons. American Journal of Physiology - Heart and Circulatory Physiology, 0, , .	3.2	0
713	Implantable cardioverter defibrillators for primary prevention in patients with ischemic and non-ischemic cardiomyopathy: A meta-analysis. Current Problems in Cardiology, 2024, 49, 102198.	2.4	0
714	Co-exposure to multiple air pollutants, genetic susceptibility, and the risk of myocardial infarction onset: A cohort analysis of the UK Biobank participants. European Journal of Preventive Cardiology, 0, , .	1.8	0
715	Treatmentâ€seeking behavior and cardiovascular morbidity among men with anabolicâ€androgenic steroid use: AÂcrossâ€sectional study. Scandinavian Journal of Medicine and Science in Sports, 2024, 34, .	2.9	0
716	The Role of the Wearable Defibrillator in Heart Failure. Current Heart Failure Reports, 2024, 21, 33-42.	3.3	0
717	Efficacy and safety of <scp>CDR132L</scp> in patients with reduced left ventricular ejection fraction after myocardial infarction: Rationale and design of the <scp>HFâ€REVERT</scp> trial. European Journal of Heart Failure, 0, , .	7.1	1
718	Left ventricular ejection fraction: clinical, pathophysiological, and technical limitations. Frontiers in Cardiovascular Medicine, 0, 11, .	2.4	0
719	Dapagliflozin Pretreatment Prevents Cardiac Electrophysiological Changes in a Diet and Streptozotocin Induction of Type 2 Diabetes in Rats: A Potential New First-Line?. Journal of Experimental Pharmacology, 0, Volume 16, 123-133.	3.2	0
720	Management of Acute Myocardial Infarction Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. , 2024, 3, 43.		0
721	Dapagliflozin in patients with heart failure and previous myocardial infarction: A participantâ€level pooled analysis of <scp>DAPAâ€HF</scp> and <scp>DELIVER</scp> . European Journal of Heart Failure, 0, ,	7.1	0